Browse Locations ... - Conditions: Lymphoblastic Leukemia, Acute, Childhood; Myelogenous Leukemia, Acute, Childhood
Interventions: Drug: Azacitidine; Drug: Fludarabine; Drug: Cytarabine
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium; Gateway for Cancer Research; USC/Norris Comprehensive Cancer Center
Not yet recruiting - verified May 2013 - Conditions: Anal Squamous Intraepithelial Lesion (ASIL); HPV DNA
Intervention: Procedure: Anal Pap smear and HPV DNA testing
Sponsors: Stanford University; Stanford University
Recruiting - verified May 2013 - Condition: Atopic Dermatitis
Interventions: Drug: Dupilumab (REGN668/ SAR231893); Drug: Placebo
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi
Recruiting - verified May 2013 - Conditions: Epithelial Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatous Mesothelioma; Stage II Malignant Mesothelioma; Stage III Malignant Mesothelioma; Stage IV Malignant Mesothelioma
Interventions: Drug: tivantinib; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Full Iris Defects; Partial Iris Defects
Intervention: Device: Artificial Iris (CustomFlex)
Sponsors: HumanOptics AG; HumanOptics AG
Not yet recruiting - verified May 2013 - Conditions: Methamphetamine Dependence; HIV Infection
Interventions: Drug: Ibudilast; Drug: Placebo
Sponsors: University of California, Los Angeles; University of California, Los Angeles; National Institute on Drug Abuse (NIDA)
Not yet recruiting - verified May 2013 - Conditions: Reading Disability; Dyslexia
Intervention:
Sponsors: Scripps Health; Scripps Health
Not yet recruiting - verified May 2013 - Conditions: Peripheral Arterial Disease; Diabetic Foot
Interventions: Biological: 3 x 10^6 cells; Biological: 10 x 10^6 cells; Biological: 30 x 10^6 cells; Biological: 100 x 10^6 cells
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2013 - Condition: Chronic Hepatitis C
Interventions: Drug: PPI-668; Drug: BI 207127 Dose 1; Drug: BI 207127 Dose 2; Drug: Faldaprevir; Drug: Ribavirin; Drug: BI 207127 Placebo
Sponsors: Presidio Pharmaceuticals, Inc.; Presidio Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Obesity
Intervention: Genetic: Personalized Genomics
Sponsors: University of California, San Diego; University of California, San Diego
Recruiting - verified May 2013 - Conditions: Insulin Secretion; Insulin Resistance
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified May 2013 - Conditions: Asthma; Chronic Obstructive Pulmonary Disease (COPD)
Intervention: Drug: Albuterol Spiromax®
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Not yet recruiting - verified May 2013 - Conditions: Coronary Artery Disease; Coronary Arteriosclerosis
Intervention:
Sponsors: MDDX LLC; MDDX LLC; GE Healthcare
Recruiting - verified May 2013 - Condition: Prostatic Neoplasms
Interventions: Drug: VT-122; Drug: Placebo
Sponsors: Vicus Therapeutics; Vicus Therapeutics
Not yet recruiting - verified May 2013 - Condition: Lymphoma
Interventions: Drug: Ibrutinib; Drug: Placebo; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Prednisone
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Not yet recruiting - verified May 2013 - Conditions: Kidney Transplantation; Transplantation
Interventions: Biological: Anti-thymocyte Globulin (Rabbit); Biological: Belatacept; Drug: Methylprednisolone; Biological: basiliximab; Drug: Mycophenolate Acid; Drug: Tacrolimus
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Clinical Trials in Organ Transplantation (CTOT)
Not yet recruiting - verified May 2013 - Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: GFF MDI; Drug: GP MDI; Drug: FF MDI; Drug: Open-label tiotropium bromide inhalation powder; Drug: Placebo MDI
Sponsors: Pearl Therapeutics, Inc.; Pearl Therapeutics, Inc.
Not yet recruiting - verified May 2013 - Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: GFF MDI (PT003); Drug: GP MDI (PT001); Drug: FF MDI (PT005); Drug: Placebo
Sponsors: Pearl Therapeutics, Inc.; Pearl Therapeutics, Inc.
Not yet recruiting - verified May 2013 - Condition: Healthy
Interventions: Drug: NRX-1074; Drug: Placebo
Sponsors: Naurex, Inc; Naurex, Inc
Recruiting - verified May 2013 - Condition: Hepatitis C
Intervention: Drug: SOF in combination with GS-5816
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Condition: Congestive Heart Failure
Interventions: Drug: D-ribose; Other: Placebo
Sponsors: RiboCor, Inc.; RiboCor, Inc.
Not yet recruiting - verified May 2013 - Condition: Urinary Incontinence
Intervention: Biological: OnabotulinumtoxinA
Sponsors: Allergan; Allergan
Not yet recruiting - verified May 2013 - Condition: Primary Immune Deficiency Syndrome (PID)
Intervention: Biological: Octagam or other marketed IVIG product
Sponsors: Octapharma; Octapharma
Not yet recruiting - verified May 2013 - Condition: Urinary Incontinence
Intervention: Biological: OnabotulinumtoxinA
Sponsors: Allergan; Allergan
Not yet recruiting - verified May 2013 - Conditions: Fibromyalgia; Chronic Pain; Myofascial Pain
Intervention: Drug: IMC-1
Sponsors: Innovative Med Concepts, LLC; Innovative Med Concepts, LLC
Recruiting - verified May 2013 - Conditions: Trisomy 21; Trisomy 18; Trisomy 13; Sex Chromosome Abnormalities; Microdeletion Syndromes
Intervention:
Sponsors: Natera, Inc.; Natera, Inc.
Recruiting - verified May 2013 - Condition: Chronic Hepatitis C Virus
Interventions: Drug: Sofosbuvir/Ledipasvir 400/90 mg; Drug: Ribavirin
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Condition: Blepharoptosis
Intervention: Drug: RVL-1201
Sponsors: RevitaLid Inc.; RevitaLid Inc.
Recruiting - verified May 2013 - Conditions: Opioid-Related Disorders,; Opiate Dependence
Interventions: Drug: OX219 buprenorphine/naloxone; Drug: Buprenorphine
Sponsors: Orexo AB; Orexo AB; Worldwide Clinical Trials
Not yet recruiting - verified May 2013 - Condition: Vitamin D Deficiency
Interventions: Dietary Supplement: Vitamin D2; Dietary Supplement: Vitamin D3
Sponsors: University of California, Los Angeles; University of California, Los Angeles
Recruiting - verified May 2013 - Conditions: Benign Prostatic Hyperplasia; BPH; Lower Urinary Tract Symptoms (LUTS); LUTS; Enlarged Prostate
Intervention: Drug: NX-1207
Sponsors: Nymox Corporation; Nymox Corporation
Recruiting - verified May 2013 - Condition: Hyperlipidemia and Mixed Dyslipidemia
Interventions: Drug: AMG 145 and standard of care; Other: Standard of care
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Condition: Non-Small Cell Lung Cancer
Intervention: Drug: MPDL3280A
Sponsors: Genentech; Genentech
Not yet recruiting - verified May 2013 - Conditions: Healthy, no Evidence of Disease; Localized Transitional Cell Cancer of the Renal Pelvis and Ureter; Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter; Psychosocial Effects of Cancer and Its Treatment; Recurrent Bladder Cancer; Recurrent Cervical Cancer; Recurrent Colon Cancer; Recurrent Gastric Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Pancreatic Cancer; Recurrent Rectal Cancer; Recurrent Renal Cell Cancer; Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter; Recurrent Urethral Cancer; Recurrent Uterine Sarcoma; Regional Transitional Cell Cancer of the Renal Pelvis and Ureter; Stage II Bladder Cancer; Stage II Renal Cell Cancer; Stage II Urethral Cancer; Stage IIA Cervical Cancer; Stage IIA Colon Cancer; Stage IIA Gastric Cancer; Stage IIA Ovarian Epithelial Cancer; Stage IIA Ovarian Germ Cell Tumor; Stage IIA Pancreatic Cancer; Stage IIA Rectal Cancer; Stage IIA Uterine Sarcoma; Stage IIB Cervical Cancer; Stage IIB Colon Cancer; Stage IIB Gastric Cancer; Stage IIB Ovarian Epithelial Cancer; Stage IIB Ovarian Germ Cell Tumor; Stage IIB Pancreatic Cancer; Stage IIB Rectal Cancer; Stage IIB Uterine Sarcoma; Stage IIC Colon Cancer; Stage IIC Ovarian Epithelial Cancer; Stage IIC Ovarian Germ Cell Tumor; Stage IIC Rectal Cancer; Stage III Bladder Cancer; Stage III Pancreatic Cancer; Stage III Renal Cell Cancer; Stage III Urethral Cancer; Stage IIIA Cervical Cancer; Stage IIIA Colon Cancer; Stage IIIA Gastric Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIA Ovarian Germ Cell Tumor; Stage IIIA Rectal Cancer; Stage IIIA Uterine Sarcoma; Stage IIIB Cervical Cancer; Stage IIIB Colon Cancer; Stage IIIB Gastric Cancer; Stage IIIB Ovarian Epithelial Cancer; Stage IIIB Ovarian Germ Cell Tumor; Stage IIIB Rectal Cancer; Stage IIIB Uterine Sarcoma; Stage IIIC Colon Cancer; Stage IIIC Gastric Cancer; Stage IIIC Ovarian Epithelial Cancer; Stage IIIC Ovarian Germ Cell Tumor; Stage IIIC Rectal Cancer; Stage IIIC Uterine Sarcoma; Stage IV Bladder Cancer; Stage IV Gastric Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Pancreatic Cancer; Stage IV Renal Cell Cancer; Stage IV Urethral Cancer; Stage IVA Cervical Cancer; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVA Uterine Sarcoma; Stage IVB Cervical Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer; Stage IVB Uterine Sarcoma; Ureter Cancer
Interventions: Other: educational intervention; Behavioral: telephone-based intervention; Procedure: quality-of-life assessment; Other: questionnaire administration
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Not yet recruiting - verified May 2013 - Condition: Sleep Initiation and Maintenance Disorders
Interventions: Behavioral: Arousal Based Therapy for Insomnia; Behavioral: Cognitive Behavioral Therapy for Insomnia
Sponsors: Stanford University; Stanford University; National Institute of Nursing Research (NINR); University of San Diego
Recruiting - verified April 2013 - Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: decitabine; Drug: midostaurin; Other: laboratory biomarker analysis
Sponsors: Stanford University; Bruno C. Medeiros; National Cancer Institute (NCI)
Not yet recruiting - verified April 2013 - Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Commercial Hylenex® recombinant (hyaluronidase human injection); Drug: Pre-commercial formulation of Hylenex recombinant (hyaluronidase human injection); Procedure: Preadministration of commercial Hylenex® recombinant (hyaluronidase human injection); Procedure: Preadministration of pre-commercial Hylenex recombinant (hyaluronidase human injection); Device: Continuous Subcutaneous Insulin Infusion (CSII) via insulin infusion pumps
Sponsors: Halozyme Therapeutics; Halozyme Therapeutics
Recruiting - verified May 2013 - Condition: Anesthesia
Interventions: Drug: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%; Drug: Placebo
Sponsors: St. Renatus, LLC; St. Renatus, LLC; Triligent International; Tegra Analytics
Not yet recruiting - verified April 2013 - Condition: Generalized Anxiety Disorder
Interventions: Drug: Placebo; Drug: Vilazodone
Sponsors: Forest Laboratories; Forest Laboratories
Not yet recruiting - verified April 2013 - Condition: Multiple Myeloma
Interventions: Drug: MLN9708 + Lenalidomide + Dexamethasone; Drug: Placebo + Lenalidomide + Dexamethasone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2013 - Condition: Unwanted, Non Cosmetic, Tattoos
Intervention: Device: 755 nm alexandrite laser
Sponsors: Cynosure, Inc.; Cynosure, Inc.
Recruiting - verified April 2013 - Condition: Vulvovaginal Atrophy
Interventions: Drug: Estradiol Vaginal Gel; Drug: Vehicle
Sponsors: Warner Chilcott; Warner Chilcott
Recruiting - verified April 2013 - Conditions: Pediatric Solid Tumor; Sarcoma; Neuroblastoma; Wilms Tumor
Intervention:
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Recruiting - verified May 2013 - Condition: Hepatic Encephalopathy
Interventions: Drug: Placebo; Drug: Rifaximin
Sponsors: Salix Pharmaceuticals; Salix Pharmaceuticals
Recruiting - verified April 2013 - Conditions: Chlamydial Infection; Gonococcal Infection
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco
Not yet recruiting - verified May 2013 - Conditions: Bilateral Cochlear Aplasia; Bilateral Cochlear Nerve Deficiency; Bilateral Cochlear Ossification Secondary to Meningitis
Intervention: Device: Auditory brainstem implant
Sponsors: House Research Institute; House Research Institute; House Clinic; Children's Hospital Los Angeles
Not yet recruiting - verified May 2013 - Condition: Jaw, Edentulous, Partially
Interventions: Device: Titanium dental implant; Device: Roxolid dental implant
Sponsors: Institut Straumann AG; Institut Straumann AG
Recruiting - verified April 2013 - Conditions: Gastroesophageal Reflux; Respiratory Aspiration; Idiopathic Pulmonary Fibrosis; Lung Transplantation
Intervention: Drug: Cromolyn Sodium
Sponsors: University of California, San Francisco; University of California, San Francisco; Aradign Corportation; National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting - verified April 2013 - Condition: Major Depressive Disorder
Intervention: Drug: Cariprazine
Sponsors: Forest Laboratories; Forest Laboratories; Gedeon Richter Ltd.
Not yet recruiting - verified April 2013 - Condition: Spinal Muscular Atrophy
Intervention: Drug: ISIS-SMNRx
Sponsors: Isis Pharmaceuticals; Isis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Cutaneous Lupus Erythematosus
Intervention: Drug: IVIg
Sponsors: University of California, Irvine; University of California, Irvine; Grifols Therapeutics Inc.
Recruiting - verified April 2013 - Condition: Facial Wrinkles
Intervention: Device: TriPollar
Sponsors: Pollogen; Pollogen
Recruiting - verified May 2013 - Condition: Multiple Myeloma
Intervention:
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AbbVie
Recruiting - verified April 2013 - Condition: Asthma
Interventions: Drug: Albuterol Spiromax®; Drug: ProAir® HFA
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified April 2013 - Condition: Breast Cancer
Intervention: Drug: Reparixin
Sponsors: Dompé s.p.a.; Dompé s.p.a.
Recruiting - verified May 2013 - Condition: Alzheimer Disease
Interventions: Biological: LY3002813-IV; Biological: LY3002183-SC; Drug: Placebo-IV
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Breast Cancer
Intervention: Procedure: Cryoablation
Sponsors: John Wayne Cancer Institute; John Wayne Cancer Institute
Recruiting - verified May 2013 - Conditions: Lung Cancer; Esophageal
Intervention:
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center; Pinnacle Biologics Inc.
Recruiting - verified April 2013 - Condition: X-linked Myotubular Myopathy
Intervention:
Sponsors: Cure CMD; Cure CMD; Congenital Muscle Disease International Registry (CMDIR); University of Michigan
Recruiting - verified April 2013 - Condition: Hepatitis C Virus
Interventions: Drug: sovaprevir; Drug: ACH-3102; Drug: Ribavirin; Drug: Placebo
Sponsors: Achillion Pharmaceuticals; Achillion Pharmaceuticals
Recruiting - verified May 2013 - Condition: Ectropion
Interventions: Procedure: Hyaluronic acid; Procedure: Saline
Sponsors: University of California, Los Angeles; University of California, Los Angeles
Recruiting - verified April 2013 - Conditions: Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Lupus Vasculitis, Central Nervous System; Lupus Nephritis
Intervention: Drug: milatuzumab
Sponsors: Immunomedics, Inc.; Immunomedics, Inc.; Department of Defense
Not yet recruiting - verified April 2013 - Condition: Advanced or Inoperable Malignant Melanoma With BRAF Mutation
Interventions: Drug: P1446A-05; Drug: Vemurafenib (Zelboraf®)
Sponsors: Piramal Enterprises Limited; Piramal Enterprises Limited; Melanoma Research Foundation Breakthrough Consortium
Not yet recruiting - verified April 2013 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Ranolazine; Drug: Placebo; Drug: Exenatide
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2013 - Conditions: Hepatic Encephalopathy; Cirrhosis
Interventions: Drug: Rifaximin; Drug: Rifaximin and Lactulose
Sponsors: Salix Pharmaceuticals; Salix Pharmaceuticals
Recruiting - verified April 2013 - Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: QVA149; Drug: fluticasone/salmeterol
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2013 - Condition: Chronic Idiopathic Constipation
Interventions: Drug: Elobixibat 10 mg; Drug: Elobixibat 5 mg; Drug: Placebo
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Recruiting - verified May 2013 - Condition: HIV-associated Enteropathy
Intervention: Other: Serum-derived bovine immunoglobulin protein isolate (SBI)
Sponsors: Entera Health, Inc; Entera Health, Inc
Recruiting - verified April 2013 - Condition: Chronic Idiopathic Constipation
Interventions: Drug: Elobixibat 10 mg; Drug: Elobixibat 5 mg; Drug: Placebo
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Recruiting - verified May 2013 - Condition: Breast Cancer
Intervention:
Sponsors: Provista Diagnostics, Inc; Provista Diagnostics, Inc
Recruiting - verified April 2013 - Condition: Recovery Following Primary Total Knee Arthroplasty
Interventions: Procedure: Formal Rehabilitation Therapy; Procedure: Independent Exercise Cohort
Sponsors: University of California, San Francisco; University of California, San Francisco
Not yet recruiting - verified May 2013 - A Multi-center, Randomized Study in Subjects With Primary Hypercholesterolemia or Mixed DyslipidemiaCondition: Primary Hypercholesterolemia or Mixed Dyslipidemia
Intervention: Device: AMG 145
Sponsors: Amgen; Amgen
Not yet recruiting - verified May 2013 - Condition: Diabetic Foot Ulcers
Interventions: Device: Electrohydraulic-generated shock wave; Device: Sham device plus standard of care
Sponsors: SANUWAVE, Inc.; SANUWAVE, Inc.
Recruiting - verified May 2013 - Condition: Prostate Cancer
Intervention: Drug: Cabozantinib
Sponsors: Cedars-Sinai Medical Center; Edwin Posadas, MD
Recruiting - verified May 2013 - Condition: Interstitial Cystitis
Interventions: Drug: LiRIS 400 mg; Other: LiRIS Placebo
Sponsors: TARIS Biomedical, Inc.; TARIS Biomedical, Inc.
Recruiting - verified May 2013 - Condition: Asthma
Interventions: Drug: Placebo; Drug: JNJ-38518168
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Not yet recruiting - verified May 2013 - Condition: Type 2 Diabetes Mellitus (T2DM)
Interventions: Drug: PE0139 Injection; Drug: Placebo
Sponsors: PhaseBio Pharmaceuticals Inc.; PhaseBio Pharmaceuticals Inc.
Recruiting - verified May 2013 - Conditions: Muscular Dystrophy, Duchenne; Muscular Dystrophies; Muscular Disorders, Atrophic; Muscular Diseases; Musculoskeletal Diseases; Neuromuscular Diseases; Nervous System Diseases; Genetic Diseases, X-Linked; Genetic Diseases, Inborn
Interventions: Drug: Ataluren; Drug: Placebo
Sponsors: PTC Therapeutics; PTC Therapeutics
Recruiting - verified April 2013 - Condition: Breast Cancer
Intervention: Biological: Margetuximab
Sponsors: MacroGenics; MacroGenics
Recruiting - verified May 2013 - Conditions: HIV; HIV Infections
Intervention: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Condition: Hepatitis C, Chronic
Interventions: Drug: Faldaprevir; Drug: BI 207127; Drug: BI 207127 high dose; Drug: Ribavirin placebo; Drug: Faldaprevir; Drug: BI 207127 high dose; Drug: BI 207127; Drug: Faldaprevir; Drug: BI 207127 high dose placebo; Drug: Ribavirin; Drug: Faldaprevir; Drug: Faldaprevir placebo; Drug: BI 207127 low dose; Drug: BI 207127 low dose placebo; Drug: Faldaprevir; Drug: BI 207127 low dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Conditions: Hepatitis B; Hepatitis C; HIV; Drug Addiction
Interventions: Behavioral: Parolee Comprehensive Care + Phone Coach; Behavioral: Parolee Brief HBV Program + Phone Coach; Behavioral: Usual Care Group
Sponsors: University of California, Los Angeles; University of California, Los Angeles
Recruiting - verified April 2013 - Condition: Hypogonadism
Interventions: Drug: Testosterone Solution; Drug: Placebo Solution
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2013 - Condition: Basal Cell Carcinoma
Interventions: Drug: vismodegib; Drug: vismodegib; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Healthy Volunteer
Intervention: Drug: inclacumab
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified May 2013 - Conditions: Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor
Interventions: Biological: HSPPC-96; Biological: bevacizumab
Sponsors: Alliance for Clinical Oncology Trials; Alliance for Clinical Oncology Trials; National Cancer Institute (NCI); Agenus, Inc.
Recruiting - verified March 2013 - Condition: Diabetes Mellitus
Interventions: Drug: MK-3102; Drug: Placebo to MK-3102; Drug: Metformin
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Diabetic Foot Ulcers
Interventions: Drug: DSC127; Drug: placebo vehicle gel
Sponsors: Derma Sciences, Inc.; Derma Sciences, Inc.; Integrium
Recruiting - verified April 2013 - GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular UltrasoundCondition: Hypercholesterolemia
Interventions: Drug: AMG 145; Other: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Condition: Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions: Drug: LCQ908; Drug: placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified April 2013 - Condition: Autism
Intervention:
Sponsors: SynapDx; SynapDx
Recruiting - verified May 2013 - Condition: Acute Bacterial Skin and Skin Structure Infections
Interventions: Drug: Delafloxacin; Drug: Vancomycin; Drug: Aztreonam; Drug: Placebo
Sponsors: Rib-X Pharmaceuticals, Inc.; Rib-X Pharmaceuticals, Inc.
Recruiting - verified May 2013 - Condition: Healthy
Interventions: Drug: JNJ-54452840; Other: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Not yet recruiting - verified May 2013 - Condition: Normal and Ocular Pathology.
Intervention:
Sponsors: Topcon Medical Systems, Inc.; Topcon Medical Systems, Inc.
Recruiting - verified April 2013 - Conditions: Intracerebral Hemorrhage; Ischemic Stroke
Interventions: Drug: Glycerly Trinitrate; Drug: Glycerly Trinitrate; Drug: Glycerly Trinitrate
Sponsors: University of California, Los Angeles; University of California, Los Angeles
Recruiting - verified May 2013 - Conditions: Single Sided Deafness; Conductive Hearing Loss
Intervention: Device: SoundBite Hearing System
Sponsors: Sonitus Medical Inc; Sonitus Medical Inc
Recruiting - verified May 2013 - Condition: Schizophrenia
Interventions: Drug: PF-02545920; Drug: PF-02545920; Drug: PF-02545920; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Muscle Cramps in Amyotrophic Lateral Sclerosis
Interventions: Drug: Mexiletine; Drug: Placebo
Sponsors: University of California, Davis; Bjorn Oskarsson, MD; University of California, Davis
Recruiting - verified May 2013 - Condition: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Drug: Nuedexta; Drug: Matching Placebo
Sponsors: Center for Neurologic Study, La Jolla, California,; Center for Neurologic Study, La Jolla, California,; ALS Association; State University of New York - Upstate Medical University
Recruiting - verified May 2013 - Condition: Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Interventions: Drug: Ivacaftor; Drug: Lumacaftor; Drug: Ivacaftor Placebo; Drug: Lumacaftor Placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2013 - Condition: HER2+ Metastatic Breast Cancer (MBC)
Interventions: Drug: neratinib; Drug: capecitabine; Drug: lapatinib; Drug: capecitabine
Sponsors: Puma Biotechnology, Inc.; Puma Biotechnology, Inc.
Recruiting - verified May 2013 - Condition: Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Interventions: Drug: Ivacaftor; Drug: Lumacaftor; Drug: Ivacaftor Placebo; Drug: Lumacaftor Placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2013 - Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma; Diffuse Large B-cell Lymphoma
Intervention: Drug: PCI-32765 (Ibrutinib)
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Not yet recruiting - verified May 2013 - Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: afatinib; Drug: loperamide
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Osteoporosis
Interventions: Drug: odanacatib; Other: placebo to odanacatib
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Conditions: Breast Cancer; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer
Interventions: Dietary Supplement: dietary intervention; Procedure: nutritional support; Other: laboratory biomarker analysis
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: idarubicin; Drug: vorinostat; Other: laboratory biomarker analysis; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Multiple Sclerosis
Interventions: Drug: rHIgM22 first dose; Drug: rHIgM22 second escalated dose; Drug: rHIgM22 third escalated dose; Drug: rHIgM22 fourth escalated dose; Drug: rHIgM22 fifth escalated dose; Drug: rHIgM22 sixth escalated dose
Sponsors: Acorda Therapeutics; Acorda Therapeutics; PRA International
Recruiting - verified May 2013 - Condition: Pneumonia, Bacterial
Interventions: Drug: Amikacin Inhalation Solution (BAY41-6551); Drug: Aerosolized Placebo
Sponsors: Bayer; Bayer; Nektar Therapeutics; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: RO5452802; Drug: erlotinib [Tarceva]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Conditions: HIV; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; Drug: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Condition: Sickle Cell Disease
Interventions: Drug: Prasugrel; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Daiichi Sankyo Inc.
Recruiting - verified May 2013 - Condition: Metastatic Breast Cancer
Interventions: Drug: Fulvestrant; Drug: Everolimus; Drug: Placebo (for Everolimus)
Sponsors: PrECOG, LLC.; PrECOG, LLC.; Novartis
Recruiting - verified May 2013 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Linagliptin 5mg
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Type 1 Diabetes Mellitus
Interventions: Drug: LY2605541; Drug: Insulin Lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Conditions: Infant, Newborn; Infant, Moderate Preterm
Intervention:
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR)
Recruiting - verified February 2013 - Condition: Giant Cell Arteritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab placebo; Drug: prednisone; Drug: prednisone placebo; Drug: tocilizumab [RoActemra/Actemra]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified May 2013 - Condition: Pulmonary Arterial Hypertension
Intervention:
Sponsors: United Therapeutics; United Therapeutics
Recruiting - verified May 2013 - Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib; Drug: Bortezomib; Drug: Melphalan; Drug: Prednisone
Sponsors: Onyx Pharmaceuticals; Onyx Therapeutics, Inc.
Recruiting - verified May 2013 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2605541; Drug: Human Insulin NPH
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Conditions: T-cell Acute Lymphoblastic Leukemia; Intermediate/Advanced Hodgkins; Early Hodgkins
Interventions: Other: Diagnostic/symptom checklist; Other: Anthropometry; Procedure: Echocardiogram; Procedure: Serum Biomarkers; Other: 6 minute walk test (6MWT); Behavioral: Participant Questionnaires (ages ≥14 years only)
Sponsors: Children's Oncology Group; Children's Oncology Group; The Leukemia and Lymphoma Society; St. Baldrick's Foundation; National Cancer Institute (NCI)
Not yet recruiting - verified April 2013 - Condition: Osteoarthritis
Interventions: Device: Univers™; Device: Eclipse™ Total Shoulder Replacement
Sponsors: Arthrex, Inc.; Arthrex, Inc.
Recruiting - verified May 2013 - Condition: Low Back Pain
Interventions: Drug: Hydrocodone bitartrate extended-release tablets; Drug: Matching placebo
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified April 2013 - Condition: Cluster Headache
Interventions: Device: GammaCore; Device: Sham GammaCore device
Sponsors: ElectroCore LLC; ElectroCore LLC
Recruiting - verified May 2013 - Condition: Hypertension
Interventions: Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106); Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106); Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106); Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Sponsors: Bayer; Bayer
Recruiting - verified May 2013 - Conditions: Burkitt Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Precursor B-cell Lymphoblastic Leukemia-Lymphoma
Intervention: Drug: SGN-CD19A
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified May 2013 - Condition: Hypertension, Pulmonary
Intervention: Drug: Riociguat (BAY 63-2521)
Sponsors: Bayer; Bayer
Available - verified April 2013 - Condition: Advanced or Metastatic Melanoma
Interventions: Biological: Nivolumab; Biological: Ipilimumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013 - Condition: Idiopathic Parkinson's Disease
Interventions: Drug: Rotigotine; Other: Placebo
Sponsors: UCB, Inc.; UCB BIOSCIENCES GmbH
Recruiting - verified May 2013 - Condition: Kidney Transplantation
Interventions: Drug: ASKP1240; Drug: Tacrolimus; Drug: Mycophenolate Mofetil (MMF); Drug: Basiliximab; Drug: Corticosteroids
Sponsors: Astellas Pharma Inc; Astellas Pharma Global Development, Inc.; Kyowa Hakko Kirin Company, Limited
Recruiting - verified April 2013 - Condition: HIV Infections
Intervention: Drug: Raltegravir
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2013 - Condition: Lymphoma
Intervention: Drug: PCI-32765 (Ibrutinib)
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Recruiting - verified May 2013 - Conditions: Bladder Cancer; Urothelial Carcinoma
Interventions: Drug: OGX-427; Drug: Docetaxel
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; OncoGenex Technologies, Inc.
Recruiting - verified May 2013 - Condition: Mantle Cell Lymphoma
Interventions: Drug: Bendamustine; Drug: Rituximab; Drug: Ibrutinib; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Recruiting - verified May 2013 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773; Drug: BI 10773 Placebo; Drug: BI 10773 / BI 1356; Drug: BI 10773; Drug: BI 10773 / BI 1356; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773 / BI 1356 Placebo; Drug: BI 10773 / BI 1356 Placebo; Drug: BI 10773; Drug: BI 10773 / BI 1356 Placebo; Drug: BI 10773 Placebo; Drug: BI 10773; Drug: BI 10773 / BI 1356 Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Plaque Psoriasis
Interventions: Drug: Ixekizumab Auto-Injector; Drug: Ixekizumab Prefilled Syringe
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Migraine Disorders
Intervention: Device: Occipital nerve stimulator
Sponsors: Boston Scientific Corporation; Boston Scientific Corporation
Recruiting - verified May 2013 - Conditions: Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell
Interventions: Drug: cyclophosphamide; Drug: doxorubicin; Drug: vincristine; Drug: prednisone; Drug: brentuximab vedotin
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2013 - Condition: Hemophilia A
Intervention: Biological: BAY94-9027
Sponsors: Bayer; Bayer
Not yet recruiting - verified May 2013 - Condition: Diabetes Mellitus, Type 2
Intervention: Drug: Human Regular U-500 Insulin
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Carcinoma, Hepatocellular
Interventions: Drug: Regorafenib (BAY73-4506); Drug: Placebo
Sponsors: Bayer; Bayer
Not yet recruiting - verified April 2013 - Conditions: Modified Release Oral Formulation; Left Ventricular Systolic Dysfunction; Chronic Heart Failure; History of Chronic Heart Failure; Left Ventricular Ejection Fraction; Pharmacokinetics; Echocardiogram
Interventions: Drug: Omecamtiv mecarbil; Drug: Omecamtiv mecarbil; Drug: Placebo; Drug: Omecamtiv Mecarbil; Drug: Omecamtiv Mecarbil
Sponsors: Amgen; Amgen; Cytokinetics
Recruiting - verified April 2013 - Condition: Migraine
Intervention: Biological: ALD403
Sponsors: Alder Biopharmaceuticals, Inc.; Alder Biopharmaceuticals, Inc.
Recruiting - verified April 2013 - Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: trastuzumab
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; German Breast Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified May 2013 - Condition: Schizophrenia
Intervention: Behavioral: TARA computer-based exercises
Sponsors: Posit Science Corporation; Posit Science Corporation; National Institute for Health Research, United Kingdom
Recruiting - verified May 2013 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Umeclidinium bromide 62.5mcg; Drug: Umeclidinium bromide 125mcg; Drug: Fluticasone propionate 250mcg/Salmeterol 50mcg
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Conditions: HIV; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; Drug: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Condition: Kidney Transplantation
Intervention: Other: Dose adjust group (NFAT)
Sponsors: University of California, San Francisco; University of California, San Francisco; Astellas Pharma Inc
Recruiting - verified May 2013 - Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: Simtuzumab (GS-6624); Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Placebo; Drug: Dulaglutide; Drug: Glimepiride
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Squamous Non Small Cell Lung Cancer
Interventions: Drug: Necitumumab; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Conditions: ST Segment Elevation Myocardial Infarction (STEMI); Allogeneic Mesenchymal Bone Marrow Cells
Intervention: Biological: ALLOGENEIC MESENCHYMAL BONE MARROW CELLS
Sponsors: Stemedica Cell Technologies, Inc.; Stemedica Cell Technologies, Inc.; Mercy Gilbert Medical Center at AZ; Chandler Regional Medical Center at Chandler AZ; University of California, San Diego
Not yet recruiting - verified January 2013 - Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Peripheral T-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Colon Cancer; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Melanoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Rectal Cancer; Recurrent Small Lymphocytic Lymphoma; Refractory Hairy Cell Leukemia; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Testicular Lymphoma; Waldenström Macroglobulinemia
Interventions: Biological: ipilimumab; Radiation: radiation therapy; Other: laboratory biomarker analysis
Sponsors: Stanford University; Stanford University; National Cancer Institute (NCI)
Recruiting - verified April 2013 - Condition: Type 2 Diabetes
Interventions: Drug: lixisenatide (AVE0010); Drug: insulin glulisine (HMR1964)
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013 - Condition: Neoplasms
Interventions: Drug: vemurafenib; Drug: vemurafenib
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Erectile Dysfunction
Interventions: Drug: avanafil; Drug: Placebo
Sponsors: VIVUS, Inc.; VIVUS, Inc.
Recruiting - verified May 2013 - Conditions: Overactive Bladder; Urinary Incontinence
Interventions: Biological: botulinum toxin type A; Drug: solifenacin; Drug: placebo (normal saline); Drug: solifenacin placebo
Sponsors: Allergan; Allergan
Recruiting - verified May 2013 - Conditions: Amnestic Mild Cognitive Impairment; Alzheimer's Disease
Interventions: Drug: Insulin (Humulin® R U-100); Drug: Placebo
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); Alzheimer's Disease Cooperative Study (ADCS)
Not yet recruiting - verified May 2013 - Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: BMS-986020; Drug: Placebo matching with BMS-986020
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013 - Condition: Colorectal Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: leucovorin; Drug: 5-fluorouracil; Drug: irinotecan; Drug: oxaliplatin; Drug: capecitabine [Xeloda]; Drug: fluoropyrimidine-based chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Malignant Melanoma, Neoplasms
Interventions: Drug: vemurafenib; Drug: rifampin
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Malignant Melanoma, Neoplasms
Interventions: Drug: vemurafenib; Drug: ketoconazole
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Conditions: Metastatic Colorectal Cancer; Cachexia; Weight Loss
Interventions: Drug: MABp1; Drug: Megestrol Acetate
Sponsors: XBiotech, Inc.; XBiotech, Inc.
Recruiting - verified April 2013 - Condition: Ulcerative Colitis
Interventions: Drug: PF-00547659; Drug: PF-00547659
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Hyperlipidemia
Interventions: Drug: AMG 145; Drug: Ezetimibe; Other: Placebo (administered subcutaneously); Other: Placebo (administered orally)
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Condition: Hyperlipidemia
Interventions: Drug: AMG 145; Other: Placebo (administered subcutaneously); Drug: Ezetimibe; Other: Placebo (administered orally)
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Condition: Hyperlipidemia
Interventions: Drug: AMG 145; Other: Ezetimibe; Other: Placebo (administered subcutaneously); Other: Placebo (administered orally); Drug: Statin therapy
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Condition: Obesity
Interventions: Device: Aspiration Therapy (AspireAssist); Behavioral: Lifestyle Therapy
Sponsors: Aspire Bariatrics, Inc.; Aspire Bariatrics, Inc.; Boston Medical Center; Brigham and Women's Hospital; Cornell University; Howard University; Mayo Clinic; Northwestern University; St. Mary Medical Center; San Diego Veterans Healthcare System; University of Pennsylvania; Washington University School of Medicine
Recruiting - verified May 2013 - Condition: Metastatic or Unresectable Cutaneous Melanoma
Interventions: Drug: MEK162; Drug: Dacarbazine
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2013 - Conditions: Patient Adherence; HIV Seropositivity
Intervention: Device: SoC + iTab
Sponsors: California Collaborative Treatment Group; California Collaborative Treatment Group; University of California, Los Angeles; University of Southern California; City of Long Beach Department of Health and Human Services; California HIV/AIDS Research Program; Gilead Sciences
Recruiting - verified May 2013 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-0431A XR; Drug: Placebo to MK-0431A XR; Drug: Metformin XR; Drug: Placebo to metformin XR; Drug: Insulin glargine
Sponsors: Merck; Merck
Recruiting - verified April 2013 - Condition: Ulcerative Colitis
Interventions: Drug: AVX 470; Drug: Placebo
Sponsors: Avaxia Biologics, Incorporated; Avaxia Biologics, Incorporated
Recruiting - verified May 2013 - Condition: Community-acquired Bacterial Pneumonia
Interventions: Drug: Solithromycin; Drug: Moxifloxacin
Sponsors: Cempra Pharmaceuticals; Cempra Pharmaceuticals
Recruiting - verified May 2013 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: PF-05175157; Drug: Placebo; Drug: PF-05175157; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Interventions: Drug: VX-509; Drug: VX-509 matching placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2013 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3012; Drug: Matching placebo to MK-3012; Drug: Glimepiride; Drug: Matching placebo to glimepiride; Drug: Insulin glargine; Drug: Metformin
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Cytomegalovirus Infections
Interventions: Drug: RG7667; Drug: Placebo
Sponsors: Genentech; Genentech
Recruiting - verified May 2013 - Conditions: Inflammation; Crohn's Disease
Interventions: Drug: NNC0114-0006; Drug: NNC0114-0006
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013 - Condition: Duchenne Muscular Dystrophy
Intervention: Other: Observational study
Sponsors: Prosensa Therapeutics; Prosensa Therapeutics
Recruiting - verified May 2013 - Condition: Knee Osteoarthritis
Interventions: Device: Durolane; Device: PBS
Sponsors: Q-Med AB; Q-Med AB
Recruiting - verified May 2013 - Condition: Post Herpetic Neuralgia
Interventions: Drug: NXN-462; Drug: Placebo
Sponsors: NeurAxon Inc.; NeurAxon Inc.
Recruiting - verified May 2013 - Condition: Fragile X Syndrome
Interventions: Drug: RO4917523; Drug: RO4917523; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Asthma
Interventions: Drug: Albuterol Spiromax® 90 mcg/inhalation; Drug: Placebo Spiromax
Sponsors: Teva Pharmaceutical Industries; Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting - verified April 2013 - Condition: Postherpetic Neuralgia
Interventions: Drug: Z160; Drug: Placebo
Sponsors: Zalicus; Zalicus
Recruiting - verified May 2013 - Conditions: Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS)
Intervention: Drug: Treosulfan
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program; Resource for Clinical Investigation in Blood and Marrow Transplantation (RCI BMT); Pediatric Blood and Marrow Transplant Consortium; St. Baldrick's Foundation; medac GmbH
Not yet recruiting - verified May 2013 - Condition: Hyperhidrosis
Interventions: Device: miraDry; Device: Nd:YAG Laser; Device: Botox®
Sponsors: Cynosure, Inc.; Cynosure, Inc.
Recruiting - verified April 2013 - Condition: CML
Intervention: Drug: AMN107
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Advanced Idiopathic Parkinson's Disease
Interventions: Drug: Rotigotine; Drug: Placebo
Sponsors: UCB, Inc.; UCB BIOSCIENCES GmbH
Recruiting - verified May 2013 - Condition: Leukemia Lymphocytic Chronic B-Cell
Interventions: Drug: CC-292; Drug: Rituximab
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2013 - Condition: Dry Eye
Interventions: Drug: Lifitegrast; Drug: Placebo
Sponsors: SARcode Bioscience; SARcode Bioscience
Recruiting - verified May 2013 - Condition: Alzheimer's Disease
Interventions: Drug: AC-1204; Drug: Placebo
Sponsors: Accera, Inc.; Accera, Inc.
Recruiting - verified May 2013 - Conditions: Precancerous Conditions; Carcinoma
Intervention:
Sponsors: Integrated Diagnostics; Integrated Diagnostics
Recruiting - verified April 2013 - Condition: Alzheimer's Disease
Interventions: Drug: MK-8931; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Eisenmenger Syndrome
Intervention: Drug: Macitentan 10 mg tablet, once daily.
Sponsors: Actelion; Actelion
Not yet recruiting - verified May 2013 - Condition: Eisenmenger Syndrome
Interventions: Drug: Macitentan 10 mg, oral tablet, to be taken once daily.; Drug: Matching placebo oral tablet, to be taken once daily.
Sponsors: Actelion; Actelion
Recruiting - verified May 2013 - Condition: Prevent Disorders in Children Adopted From Foster Care
Intervention: Behavioral: ADAPT
Sponsors: University of California, Los Angeles; University of California, Los Angeles; Center for Adoption Support and Education; UCLA TIES for Families
Recruiting - verified May 2013 - Condition: Neoplasms
Intervention: Drug: vemurafenib
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Breast Neoplasms
Interventions: Drug: PD-0332991; Drug: Letrozole; Drug: Placebo; Drug: Letrozole
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Alzheimer's Disease
Interventions: Drug: ELND005; Drug: Placebo
Sponsors: Elan Pharmaceuticals; Elan Pharma International Limited; Elan Pharmaceuticals
Recruiting - verified May 2013 - Conditions: Diphtheria; Pertussis; Tetanus
Intervention: Biological: Boostrix
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013 - Condition: Type 1 Diabetes
Interventions: Device: Continuous Glucose Monitor; Device: home glucose meter
Sponsors: Sansum Diabetes Research Institute; Sansum Diabetes Research Institute
Recruiting - verified May 2013 - Condition: Tardive Dyskinesia
Interventions: Drug: NBI-98854; Drug: NBI-98854; Drug: Placebo
Sponsors: Neurocrine Biosciences; Neurocrine Biosciences
Recruiting - verified May 2013 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Linagliptin; Drug: Empagliflozin + Linagliptin; Drug: Empagliflozin + Linagliptin; Drug: Empagliflozin + Linagliptin; Drug: Empaglifozin placebo + Linagliptin placebo; Drug: Empagliflozin + Linagliptin
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Cystinosis
Interventions: Drug: RP103 Q12H; Drug: Cystagon Q6H
Sponsors: Raptor Therapeutics Inc.; Raptor Therapeutics Inc.
Recruiting - verified April 2013 - Conditions: Diabetes Mellitus, Non-Insulin-Dependent; High Risk for Cardiovascular Event
Interventions: Drug: Dapagliflozin 10 mg; Drug: Placebo tablet
Sponsors: AstraZeneca; AstraZeneca; Bristol-Myers Squibb; The TIMI Study Group; Hadassah Medical Organization
Recruiting - verified May 2013 - Condition: Breast Cancer
Interventions: Other: Educational DVD 1; Other: Educational DVD 2
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Condition: Melanoma
Interventions: Drug: Talimogene laherparepvec plus ipilimumab; Drug: Ipilimumab
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Conditions: B-cell Chronic Lymphocytic Leukemia; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory Hairy Cell Leukemia; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Testicular Lymphoma; Waldenström Macroglobulinemia
Interventions: Biological: ipilimumab; Biological: rituximab; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Chronic Sinusitis
Interventions: Drug: S8 sinus implant; Drug: continued nasal steroid spray
Sponsors: Intersect ENT; Intersect ENT
Recruiting - verified May 2013 - Condition: Indolent Non-Hodgkin's Lymphomas
Interventions: Drug: idelalisib; Drug: Rituximab; Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Condition: Indolent Non-Hodgkin's Lymphomas
Interventions: Drug: Rituximab IV 375mg/m2 every 28 days for 4 cycles; Drug: bendamustine 90mg/m2 for 2 consecutive days every 28 days for 4 cycles; Drug: idelalisib orally 150mg BID; Drug: Placebo orally 150mg BID
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Conditions: Pulmonary Hypertension; Chronic Obstructive Pulmonary Disease
Interventions: Drug: Inhaled nitric oxide; Other: Placebo
Sponsors: INO Therapeutics; INO Therapeutics
Recruiting - verified April 2013 - Condition: Plaque Psoriasis
Interventions: Drug: MK-3222 200 mg; Drug: MK-3222 100 mg; Drug: MK-3222 Placebo; Drug: Etanercept Placebo; Drug: Etanercept 50 mg
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Reduction of Hypertrophic Skin Scarring
Interventions: Drug: PF-06473871; Drug: PF-06473871
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: Congenital Bleeding Disorder; Haemophilia A
Intervention: Drug: NNC 0129-0000-1003
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013 - Condition: Pulmonary Arterial Hypertension
Intervention: Drug: AIR001 (sodium nitrite inhalation solution)
Sponsors: Aires Pharmaceuticals, Inc.; Aires Pharmaceuticals, Inc.
Recruiting - verified May 2013 - Condition: Pulmonary Arterial Hypertension
Intervention: Drug: AIR001
Sponsors: Aires Pharmaceuticals, Inc.; Aires Pharmaceuticals, Inc.
Recruiting - verified May 2013 - Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: tivantinib; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Chronic Hepatitis C
Interventions: Drug: VX-135; Drug: ribavirin
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified April 2013 - Condition: Hepatitis C, Chronic
Interventions: Drug: BI 207127; Drug: Ribavirin (RBV); Drug: Ribavirin (RBV); Drug: Ribavirin (RBV); Drug: BI 201335 (Faldaprevir); Drug: BI 201335 (Faldaprevir); Drug: BI 207127; Drug: BI 207127; Drug: Faldaprevir (BI 201335)
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Parkinson's Disease
Interventions: Drug: Rasagiline; Drug: Placebo
Sponsors: Teva Pharmaceutical Industries; Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting - verified April 2013 - Condition: Hepatitis C, Chronic
Interventions: Drug: BI 207127-placebo: 8-week treatment; Drug: Ribavirin: 24-week treatment; Drug: BI 207127: 24-week treatment; Drug: Faldaprevir: 24-week treatment; Drug: Faldaprevir: 24-week treatment; Drug: BI 207127: 24-week treatment; Drug: Ribavirin-placebo: 8-week treatment; Drug: Faldaprevir-placebo: 8-week treatment; Drug: Faldaprevir: 16-week treatment; Drug: Ribavirin: 16-week treatment; Drug: RBV: 24-week treatment; Drug: BI 207127: 16-week treatment
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Unresectable or Metastatic Melanoma
Interventions: Biological: BMS-936558; Drug: Dacarbazine; Drug: Carboplatin; Drug: Paclitaxel
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013 - Condition: Irritable Bowel Syndrome Characterized by Constipation
Interventions: Drug: Plecanatide; Drug: Placebo
Sponsors: Synergy Pharmaceuticals, Inc.; Synergy Pharmaceuticals, Inc.
Recruiting - verified May 2013 - Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Intervention: Drug: PCI-32765
Sponsors: Pharmacyclics; Pharmacyclics
Recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo; Drug: Baricitinib
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo; Drug: Baricitinib
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Leigh Syndrome
Interventions: Drug: Placebo; Drug: EPI-743 15 mg/kg; Drug: EPI-743 5 mg/kg
Sponsors: Edison Pharmaceuticals Inc; Edison Pharmaceuticals Inc; Axio Research. LLC; Biosoteria
Recruiting - verified May 2013 - Condition: BRAFV600E Melanoma Patients
Interventions: Drug: Dabrafenib; Procedure: Gamma Knife Radiosurgery
Sponsors: University of California, San Francisco; University of California, San Francisco; GlaxoSmithKline
Recruiting - verified May 2013 - Conditions: Diabetes Mellitus, Type 2; Hyperglycemia
Interventions: Drug: Empagliflozin low dose qd; Drug: Metformin 500 mg bid; Drug: Metformin 1000 mg bid; Drug: Empagliflozin high dose qd; Drug: Empagliflozin low dose bid; Drug: Metformin 500 mg bid; Drug: Empagliflozin high dose bid; Drug: Empagliflozin low dose bid; Drug: Metformin 1000 mg bid; Drug: Metformin 500 mg bid; Drug: Metformin 1000 mg bid; Drug: Empagliflozin high dose bid; Drug: Metformin 1000 mg bid; Drug: Empagliflozin high dose bid
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Asthma
Intervention: Drug: VR506
Sponsors: Vectura Limited; Vectura Limited
Recruiting - verified May 2013 - Condition: Pain
Intervention: Device: neurostimulation system
Sponsors: Boston Scientific Corporation; Boston Scientific Corporation
Recruiting - verified May 2013 - Condition: Binge Eating Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013 - Condition: Binge Eating Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013 - Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: PCI-32765; Drug: Chlorambucil
Sponsors: Pharmacyclics; Pharmacyclics
Recruiting - verified May 2013 - Condition: Breast Cancer
Intervention: Radiation: Computed Tomography and Mammography and Tomosynthesis
Sponsors: University of California, Davis; University of California, Davis; Hologic, Inc.
Recruiting - verified December 2012 - Condition: Prostate Cancer Metastatic
Interventions: Drug: CABAZITAXEL (XRP6258); Drug: DOCETAXEL (XRP6976); Drug: prednisone
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013 - Condition: Hypercholesterolemia
Interventions: Drug: Anacetrapib 100 mg; Drug: Placebo for anacetrapib 100 mg; Drug: Anacetrapib 25 mg; Drug: Placebo for anacetrapib 25 mg
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102; Drug: Placebo to MK-3012; Drug: Metformin; Drug: Placebo to metformin; Drug: Glimepiride
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Colorectal Cancer Metastatic
Interventions: Drug: FOLFOX6m; Device: SIR-Spheres microspheres
Sponsors: Sirtex Medical; Sirtex Medical
Recruiting - verified May 2013 - Condition: Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Dupuytren's Contracture
Intervention:
Sponsors: Auxilium Pharmaceuticals; Auxilium Pharmaceuticals
Recruiting - verified October 2012 - Condition: Fungal Infections
Intervention: Drug: Posaconazole oral suspension
Sponsors: Merck; Merck
Recruiting - verified April 2013 - Condition: Neutropenia
Interventions: Drug: HM10460A (45 μg/kg); Drug: HM10460A (135 μg/kg); Drug: HM10460A (270 μg/kg); Drug: Pegfilgrastim 6mg
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc
Recruiting - verified May 2013 - Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: insulin degludec/insulin aspart; Drug: insulin degludec; Drug: insulin aspart
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013 - Condition: Pediatric Growth Hormone Deficiency
Intervention: Drug: Experimental: VRS-317
Sponsors: Versartis Inc.; Versartis Inc.
Recruiting - verified May 2013 - Condition: Diabetic Nephropathy
Interventions: Drug: PF-04634817; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: Atrial Fibrillation; Paroxysmal AF
Intervention: Device: Catheter Ablation
Sponsors: Biosense Webster, Inc.; Biosense Webster, Inc.
Recruiting - verified February 2013 - Condition: Bone Pain in Stage I - III Breast Cancer
Interventions: Drug: Naproxen; Drug: Loratadine
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo; Drug: Adalimumab; Drug: Baricitinib
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Interventions: Drug: GRT6005 Low-Dose Range; Drug: GRT6005 High-Dose Range; Drug: Placebo; Drug: Oxycodone CR
Sponsors: Forest Laboratories; Forest Laboratories; Grünenthal GmbH
Recruiting - verified May 2013 - Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: CK-2017357; Other: Placebo tablets
Sponsors: Cytokinetics; Cytokinetics
Recruiting - verified May 2013 - Condition: Postmenopausal Osteoporosis
Interventions: Drug: Teriparatide; Drug: Risedronate; Drug: Placebo; Drug: Calcium; Drug: Vitamin D
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Conditions: Recurrent Melanoma; Recurrent Thyroid Cancer; Thyroid Gland Medullary Carcinoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: cabozantinib-s-malate; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)Condition: Hodgkin Disease
Intervention: Drug: brentuximab vedotin
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified May 2013 - Condition: Plaque Psoriasis
Interventions: Drug: (CP-6890,550) Tofacitinib; Drug: Placebo; Drug: (CP-690,550) Tofacitinib; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Interventions: Drug: sarilumab SAR153191 (REGN88); Other: placebo
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified May 2013 - Condition: Melanoma
Interventions: Biological: Ipilimumab; Drug: Chemotherapy
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013 - Condition: Non-small Cell Lung Cancer(NSCLC)
Interventions: Drug: AT13387; Drug: Crizotinib
Sponsors: Astex Pharmaceuticals; Astex Pharmaceuticals
Recruiting - verified April 2013 - Condition: Cystic Fibrosis
Intervention: Drug: ivacaftor
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated; Cystic Fibrosis Foundation
Recruiting - verified April 2013 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102; Drug: Matching placebo to MK-3012; Drug: Glimepiride; Drug: Metformin
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Hypercholesterolemia
Interventions: Drug: alirocumab (REGN727/ SAR236553); Drug: Active Comparator 1 (ezetimibe); Drug: Active Comparator 2 (atorvastatin); Other: Placebo 1 (placebo for ezetimibe atorvastatin); Other: Placebo 2 [alirocumab (REGN727/ SAR236553)]
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi
Recruiting - verified May 2013 - Condition: Thyroid Eye Disease
Interventions: Drug: Hyaluronic Acid Gel injection; Drug: Saline injection
Sponsors: University of California, Los Angeles; University of California, Los Angeles
Recruiting - verified April 2013 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Measles, Mumps and Rubella Diseases
Interventions: Biological: GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762).; Biological: Merck & Co., Inc.'s M-M-R®II (also called M-M-R Vax Pro®), combined measles-mumps-rubella virus vaccine.; Biological: Varivax® (Merck & Co., Inc.); Biological: Havrix®; Biological: Prevnar 13® (Pfizer Inc.)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Conditions: Staphylococcus Aureus Bacteremia; Methicillin-resistant Staphylococcus Aureus (MRSA) Bacteremia
Intervention: Drug: Ceftaroline fosamil
Sponsors: Cerexa, Inc.; Cerexa, Inc.
Recruiting - verified May 2013 - Condition: Neuropathic Pain
Interventions: Drug: pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Condition: Atrial Fibrillation
Intervention: Other: Patients with Atrial Fibrillation
Sponsors: Janssen Scientific Affairs, LLC; Janssen Scientific Affairs, LLC; Duke Clinical Research Institute
Recruiting - verified May 2013 - Condition: Chronic Hepatitis C Virus
Interventions: Drug: Sofosbuvir/GS-5885 400/90 mg; Drug: Ribavirin
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Conditions: Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Nonseasonal
Interventions: Biological: MK-8237 tablets; Biological: Placebo tablets; Drug: Rescue Medication: Self-Injectable Epinephrine; Drug: Rescue Medication: Loratadine tablets; Drug: Rescue Medication: Olopatadine ophthalmic drops; Drug: Rescue Medication: Mometasone furoate nasal spray
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Nonalcoholic Steatohapatitis
Interventions: Drug: Roflumilast; Drug: Pioglitazone; Drug: Placebo; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2013 - Condition: Chronic Myeloid Leukemia
Intervention: Drug: nilotinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Hormone Receptor Positive Breast Cancer
Interventions: Drug: Everolimus; Drug: Letrozole; Drug: Exemestane; Drug: Dexamethasone mouth rinse
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2013 - Condition: Idiopathic Eyelash Hypotrichosis
Interventions: Drug: bimatoprost formulation A solution; Drug: bimatoprost solution 0.03 %; Drug: vehicle of bimatoprost formulation A solution; Drug: vehicle of bimatoprost solution 0.03 %
Sponsors: Allergan; Allergan
Recruiting - verified May 2013 - Condition: Allergic Rhinitis
Interventions: Drug: Beclomethasone dipropionate (BDP) nasal aerosol; Drug: Placebo Nasal Aerosol
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified April 2013 - Condition: Malignant Neoplasm
Interventions: Biological: aldesleukin; Drug: fludarabine phosphate; Drug: cyclophosphamide; Other: laboratory biomarker analysis; Biological: NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL; Biological: dendritic cell vaccine therapy; Radiation: fludeoxyglucose F 18; Procedure: positron emission tomography
Sponsors: Jonsson Comprehensive Cancer Center; Jonsson Comprehensive Cancer Center
Recruiting - verified May 2013 - Condition: Hepatitis C
Interventions: Drug: Telaprevir; Drug: Peginterferon alfa-2b; Drug: Ribavirin
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified April 2013 - Condition: Biliary Atresia
Intervention: Drug: Intravenous immunoglobulin (IVIG)
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified May 2013 - Condition: High Risk Acute Myeloid Leukemia
Interventions: Drug: CPX-351; Drug: 7+3 (cytarabine and daunorubicin)
Sponsors: Celator Pharmaceuticals; Celator Pharmaceuticals; The Leukemia and Lymphoma Society
Recruiting - verified May 2013 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Tiotropium; Drug: Placebo matching Olodaterol; Drug: Tiotropium; Drug: Olodaterol
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Malignant Melanoma
Intervention: Biological: Ipilimumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013 - Condition: Cystic Fibrosis
Interventions: Biological: KB001-A; Biological: Placebo Comparator
Sponsors: KaloBios Pharmaceuticals; KaloBios Pharmaceuticals
Recruiting - verified May 2013 - Condition: Psoriasis, Arthritic
Interventions: Drug: ixekizumab; Drug: Placebo; Drug: Adalimumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Moderate to Severe Plaque Psoriasis
Interventions: Drug: 210 mg brodalumab; Drug: 140 mg brodalumab; Drug: ustekinumab; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Condition: Sarcopenia
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco; University of Texas
Not yet recruiting - verified May 2013 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Fibromyalgia
Interventions: Drug: TD-9855 Group 1; Drug: TD-9855 Group 2; Drug: Placebo
Sponsors: Theravance, Inc.; Theravance, Inc.
Recruiting - verified May 2013 - Condition: Asthma
Interventions: Drug: Mepolizumab; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013 - Condition: Analgesia
Intervention: Drug: Ibuprofen 600 mg Immediate Release/Extended Release Caplet
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Alzheimer's Disease
Intervention: Drug: ABT-126
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified May 2013 - Condition: Clostridium Difficile-Associated Diarrhea (CDAD)
Interventions: Drug: fidaxomicin; Drug: placebo
Sponsors: Optimer Pharmaceuticals; Optimer Pharmaceuticals
Recruiting - verified May 2013 - Condition: Adult Attention Deficit Hyperactivity Disorder
Interventions: Drug: SEP-225289; Drug: SEP-225289; Drug: Placebo
Sponsors: Sunovion; Sunovion
Recruiting - verified May 2013 - Condition: Malignant Melanoma
Interventions: Drug: vemurafenib; Drug: Placebo; Drug: GDC-0973
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Chronic Anal Fissures
Interventions: Drug: VEN 307; Drug: Placebo
Sponsors: Ventrus Biosciences, Inc; Ventrus Biosciences, Inc
Recruiting - verified May 2013 - Condition: Cocaine Dependence
Interventions: Drug: Nepicastat; Drug: Placebo
Sponsors: National Institute on Drug Abuse (NIDA); National Institute on Drug Abuse (NIDA)
Recruiting - verified May 2013 - Conditions: Inflammation; Systemic Lupus Erythematosus
Interventions: Drug: NNC0114-0006; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013 - Condition: Asthma
Interventions: Drug: Fluticasone Furoate/ Vilanterol 200/25 mcg; Drug: Fluticasone Furoate/ Vilanterol 100/25 mcg; Drug: Fluticasone Furoate 100 mcg
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Conditions: Meniscus Tears; Loose Bodies; Articular Osteoarthritis; Articular or Capsular Trauma
Intervention: Procedure: VisionScope Imaging (VSI) Exam
Sponsors: VisionScope Technologies; VisionScope Technologies
Recruiting - verified April 2013 - Condition: Cardiovascular Diseases
Interventions: Drug: Evacetrapib; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; The Cleveland Clinic
Recruiting - verified May 2013 - Condition: Moderate to Severe Plaque Psoriasis
Interventions: Drug: 210 mg brodalumab; Drug: 140 mg brodalumab; Drug: ustekinumab; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Condition: Hepatitis C Virus
Interventions: Drug: ABT-450/r; Drug: ABT-267; Drug: Ribavirin
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013 - Condition: Tardive Dyskinesia
Interventions: Drug: NBI-98854; Drug: NBI-98854; Drug: Placebo
Sponsors: Neurocrine Biosciences; Neurocrine Biosciences
Recruiting - verified May 2013 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102; Drug: MK-3102 Placebo; Drug: Glimepiride; Drug: Glimepiride Placebo; Drug: Metformin; Drug: Insulin Glargine
Sponsors: Merck; Merck
Recruiting - verified April 2013 - Condition: Schizophrenia
Intervention: Drug: Aripiprazole IM Depot
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.; H. Lundbeck A/S; Otsuka America Pharmaceutical
Recruiting - verified May 2013 - Condition: Postoperative Pain
Interventions: Drug: EXPAREL; Drug: Placebo
Sponsors: Pacira Pharmaceuticals, Inc; Pacira Pharmaceuticals, Inc
Recruiting - verified May 2013 - Condition: Diabetic Kidney Disease
Interventions: Drug: baricitinib; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Incyte Corporation
Recruiting - verified May 2013 - Condition: Narcolepsy
Interventions: Drug: ADX-N05; Drug: Placebo
Sponsors: Aerial BioPharma, LLC; Aerial BioPharma, LLC
Recruiting - verified May 2013 - Condition: Non-Small Cell Lung Cancer
Intervention: Drug: LDK378
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Non-Small Cell Lung Cancer
Intervention: Drug: LDK378
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo; Drug: JNJ-38518168 (3 mg); Drug: JNJ-38518168 (10 mg); Drug: JNJ-38518168 (30 mg)
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013 - Conditions: Degenerative Sacroiliitis; Sacroiliac Joint Disruption
Interventions: Device: iFuse Implant System; Other: Non-surgical management
Sponsors: SI-BONE, Inc.; SI-BONE, Inc.
Recruiting - verified May 2013 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin/Simvastatin FDC; Drug: Sitagliptin; Drug: Simvastatin; Drug: Placebo to sitagliptin; Drug: Placebo to simvastatin; Drug: Placebo to Sitagliptin/Simvastatin FDC; Drug: Metformin; Drug: Glimepiride
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Prostate Cancer
Interventions: Drug: AT13387 and abiraterone; Drug: AT13387 alone
Sponsors: Astex Pharmaceuticals; Astex Pharmaceuticals
Recruiting - verified April 2013 - Condition: Uncontrolled Hypertension
Intervention: Device: Neo Baroreflex Activation Therapy System
Sponsors: CVRx, Inc.; CVRx, Inc.
Recruiting - verified May 2013 - Condition: Alzheimer Disease
Interventions: Drug: RO4602522; Drug: RO4601522; Drug: placebo; Drug: donepezil; Drug: rivastigmine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2013 - Condition: Carcinoid Syndrome
Interventions: Drug: Telotristat etiprate tablets (250 mg); Drug: Placebo tablets
Sponsors: Lexicon Pharmaceuticals; Lexicon Pharmaceuticals
Recruiting - verified May 2013 - Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: insulin degludec/liraglutide; Drug: liraglutide; Drug: exenatide
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013 - Condition: Atrial Fibrillation
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939); Drug: Vitamin K antagonist (VKA)
Sponsors: Bayer; Bayer; Janssen Research & Development, LLC
Recruiting - verified April 2013 - Condition: Bipolar 1 Disorder
Interventions: Drug: ELND005; Drug: Lamotrigine; Drug: Valproic acid; Drug: Placebo
Sponsors: Elan Pharmaceuticals; Elan Pharma International Limited; Elan Pharmaceuticals
Recruiting - verified May 2013 - Condition: Diabetes Melliuts, Type 2
Interventions: Other: Placebo; Drug: 25 mg PF-05231023; Drug: 50 mg PF-05231023; Drug: 100 mg PF-05231023; Drug: 150 mg PF-05231023
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Ischemic Dilated Cardiomyopathy (IDCM)
Interventions: Biological: ixmyelocel-T; Other: Vehicle Control
Sponsors: Aastrom Biosciences; Aastrom Biosciences
Recruiting - verified May 2013 - Conditions: Traumatic Brain Injury; Posttraumatic Epilepsy
Interventions: Drug: Allopregnanolone injection; Drug: Placebo injection
Sponsors: University of California, Davis; University of California, Davis; Department of Defense
Recruiting - verified May 2013 - Conditions: HIV; Acquired Immunodeficiency Syndrome; Alcoholism; Alcoholic Intoxication; Substance-Related Disorders
Interventions: Behavioral: Motivational Interviewing; Behavioral: Email Feedback; Other: Usual Care
Sponsors: University of California, San Francisco; University of California, San Francisco; Kaiser Foundation Research Institute
Recruiting - verified May 2013 - Condition: Peanut Allergy
Interventions: Biological: Viaskin Peanut 50 mcg; Biological: Viaskin Peanut 100 mcg; Biological: Viaskin Peanut 250 mcg; Biological: Viaskin Placebo
Sponsors: DBV Technologies; DBV Technologies
Recruiting - verified April 2013 - Condition: Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
Interventions: Biological: BMS-936558; Drug: Everolimus
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharmaceutical Co. Ltd
Recruiting - verified May 2013 - Condition: Non Small Cell Lung Cancer
Interventions: Drug: AMG 386 Dose 1; Drug: AMG 386 Dose 2
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Condition: Obsessive-Compulsive Disorder
Interventions: Drug: bitopertin; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2013 - Condition: Chronic Migraine
Interventions: Device: GammaCore Active Device; Device: GammaCore Sham Device
Sponsors: ElectroCore LLC; ElectroCore LLC
Recruiting - verified April 2013 - Condition: Arthritis, Rheumatoid
Interventions: Drug: BI 695500; Drug: BI 695500; Drug: rituximab; Drug: rituximab; Drug: rituximab
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Conditions: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
Interventions: Drug: pegylated liposomal doxorubicin (PLD); Drug: VTX-2337; Drug: Placebo
Sponsors: VentiRx Pharmaceuticals Inc.; VentiRx Pharmaceuticals Inc.; Gynecologic Oncology Group
Recruiting - verified April 2013 - Condition: Metastatic Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Bevacizumab [Avastin]; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Schizophrenia
Intervention: Drug: Aripiprazole IM Depot
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.; H. Lundbeck A/S; Otsuka America Pharmaceutical
Recruiting - verified May 2013 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium bromide; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Cytomegalovirus Infections, Transplantation
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium bromide; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Acute Coronary Syndrome
Interventions: Drug: SAR236553 (REGN727); Other: placebo
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified May 2013 - Condition: Metastatic Colorectal Cancer
Intervention: Drug: Aflibercept
Sponsors: Brown University; Brown University; Rhode Island Hospital; The Miriam Hospital; University of Vermont; Virginia Mason Hospital/Medical Center; Stanford University; Comprehensive Cancer Center of Wake Forest University; Thomas Jefferson University
Recruiting - verified August 2012 - Condition: Diabetes During Pregnancy
Interventions: Drug: NPH; Drug: Insulin LISPRO; Drug: Insulin glulisine
Sponsors: Sansum Diabetes Research Institute; Sansum Diabetes Research Institute; Sanofi
Recruiting - verified May 2013 - Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: BAY80-6946
Sponsors: Bayer; Bayer
Recruiting - verified April 2013 - Conditions: Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer
Interventions: Drug: Akt inhibitor MK2206; Drug: FOLFOX regimen; Drug: selumetinib
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Ulcerative Colitis
Interventions: Drug: SAR339658; Other: Placebo
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013 - Condition: Brain Metastases From Non-small Cell Lung Cancer
Interventions: Drug: Veliparib; Drug: Veliparib; Drug: Placebo
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013 - Conditions: Deep Vein Thrombosis; Venous Thrombosis
Interventions: Drug: edoxaban tosylate; Drug: enoxaparin/unfractionated heparin; Drug: warfarin
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified April 2013 - Condition: Relapsed or Refractory Systemic Light Chain Amyloidosis
Interventions: Drug: MLN9708; Drug: Dexamethasone; Drug: Melphalan; Drug: Cyclophosphamide; Drug: Thalidomide; Drug: Lenalidomide
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2013 - Condition: Infusion Reactions
Intervention: Drug: unlicensed cord blood units
Sponsors: New York Blood Center; New York Blood Center
Recruiting - verified May 2013 - Conditions: ST-elevation MI; Hypothermia
Interventions: Device: Velomedix APLS device; Other: No Hypothermia Treatment
Sponsors: Velomedix, Inc.; Velomedix, Inc.
Recruiting - verified May 2013 - Condition: Lumbosacral Radiculopathy
Interventions: Drug: z160; Drug: Placebo
Sponsors: Zalicus; Zalicus
Recruiting - verified May 2013 - Conditions: Cancer; Infertilty
Intervention:
Sponsors: University of California, San Diego; University of California, San Diego
Recruiting - verified April 2013 - Conditions: Genital Warts; Anal Cancer; Anal Intraepithelial Neoplasia
Intervention: Biological: V503 Vaccine
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: empagliflozin (low dose qd); Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Empagliflozin (high dose qd); Drug: empagliflozin (high dose bid); Drug: Placebo; Drug: empagliflozin (low dose bid)
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: afatinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Available - verified May 2013 - Condition: Ankylosing Spondylitis
Interventions: Biological: AIN457; Biological: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Conditions: Pain; Peripheral Neuropathy; Neuropathic Pain
Interventions: Drug: Placebo; Drug: Tetrodotoxin
Sponsors: Wex Pharmaceuticals Inc.; Wex Pharmaceuticals Inc.
Recruiting - verified April 2013 - Condition: Ulcerative Colitis
Interventions: Drug: RPC1063; Drug: placebo
Sponsors: Receptos, Inc.; Receptos, Inc.
Recruiting - verified May 2013 - Condition: Chronic Myeloid Leukemia
Interventions: Drug: ponatinib; Drug: imatinib (Gleevec/ Glivec)
Sponsors: Ariad Pharmaceuticals; Ariad Pharmaceuticals
Recruiting - verified May 2013 - Condition: Psoriasis
Interventions: Drug: 80 mg ixekizumab; Drug: 50 mg etanercept; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Hypercholesterolemia
Interventions: Drug: SAR236553 (REGN727); Drug: matching placebo SAR236553 (REGN727); Drug: Ezetimibe; Drug: matching placebo for Ezetimibe
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified May 2013 - Condition: Cystic Fibrosis
Interventions: Drug: Aztreonam for Inhalation Solution (AZLI); Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified July 2012 - Condition: Gastric Cancer
Interventions: Drug: trastuzumab emtansine; Drug: trastuzumab emtansine; Drug: taxane
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Conditions: Pulmonary Arterial Hypertension; Congenital Heart Disease
Intervention: Other: observational
Sponsors: Actelion; Actelion; Canadian Heart Research Centre
Recruiting - verified May 2013 - Condition: Pyelonephritis
Intervention: Other: No intervention
Sponsors: Olive View-UCLA Education & Research Institute; Olive View-UCLA Education & Research Institute; Centers for Disease Control and Prevention; Merck
Not yet recruiting - verified May 2013 - Condition: Chronic Pain
Interventions: Device: Non Boston Scientific SCS Trial Therapy; Device: Precision Plus SCS Trial Therapy w/ OMG
Sponsors: Boston Scientific Corporation; Boston Scientific Corporation
Recruiting - verified May 2013 - Condition: Lupus Nephritis
Interventions: Biological: Placebo plus standard therapy; Biological: Belimumab 10 mg/kg plus standard therapy; Drug: Standard therapy
Sponsors: GlaxoSmithKline; Human Genome Sciences Inc., a GSK Company; GlaxoSmithKline
Recruiting - verified December 2012 - Condition: Traumatic Brain Injury
Interventions: Behavioral: Plasticity-based cognitive Remediation; Other: Computer-based cognitive activities
Sponsors: Posit Science Corporation; Posit Science Corporation; Congressionally Directed Medical Research Program (CDMRP)
Not yet recruiting - verified May 2013 - Condition: Infections
Interventions: Drug: Ceftaroline fosamil; Drug: Ceftriaxone plus vancomycin
Sponsors: Cerexa, Inc.; Cerexa, Inc.; AstraZeneca
Recruiting - verified May 2013 - Condition: Squamous Cell Non-small Cell Lung Cancer
Interventions: Biological: BMS-936558; Drug: Docetaxel
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013 - Conditions: Inflammation; Rheumatoid Arthritis
Interventions: Drug: NNC0109-0012; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013 - Conditions: Inflammation; Rheumatoid Arthritis
Interventions: Drug: NNC0109-0012; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Interventions: Biological: Rituximab-Pfizer (PF-05280586) x 3 courses; Biological: Rituximab-EU+ Rituximab-Pfizer x 2 Courses; Biological: Rituximab-US + Rituximab-Pfizer x 2 Courses
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Asthma
Interventions: Drug: MK-1029 10 mg; Drug: MK-1029 30 mg; Drug: MK-1029 150 mg; Drug: Montelukast 10 mg; Drug: Placebo; Drug: MK-1029 1 mg or 3 mg; Drug: Montelukast 10 mg + MK-1029
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Obstructive Sleep Apnea
Intervention:
Sponsors: ApniCure, Inc.; ApniCure, Inc.
Recruiting - verified May 2013 - Conditions: Labor, Induced; Cervical Ripening
Intervention: Device: Outpatient transcervical Foley balloon
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified May 2013 - Condition: Polycythemia Vera
Interventions: Drug: ruxolitinib and HU-placebo; Drug: HU and ruxolitinib-placebo
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified May 2013 - Condition: Metastatic Breast Cancer HR+, HER2-
Interventions: Drug: Fulvestrant; Drug: BKM120; Drug: BKM120 matching placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions: Drug: fingolimod; Drug: copaxone
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Perennial Allergic Rhinitis (PAR)
Intervention: Drug: Beclomethasone Dipropionate (BDP) Nasal Aerosol
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; United BioSource Corporation
Recruiting - verified April 2013 - Condition: Glioblastoma
Interventions: Drug: onartuzumab; Drug: bevacizumab; Drug: onartuzumab placebo; Drug: bevacizumab placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: HIV Infections
Interventions: Drug: MK-1439; Drug: Efavirenz; Drug: TRUVADA®
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Barrett's Esophagus
Interventions: Device: Cryoballoon Focal Ablation System - 6 seconds; Device: Cryoballoon Focal Ablation System - 8 seconds
Sponsors: C2 Therapeutics, Inc.; C2 Therapeutics, Inc.
Recruiting - verified May 2013 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Custirsen + Docetaxel; Drug: Docetaxel
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified April 2013 - Conditions: Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma
Intervention: Drug: asparaginase Erwinia chrysanthemi
Sponsors: EUSA Pharma (US), Inc.; EUSA Pharma (US), Inc.
Recruiting - verified May 2013 - Condition: Parkinson's Disease
Intervention:
Sponsors: National Parkinson Foundation; National Parkinson Foundation
Recruiting - verified May 2013 - Condition: Asthma
Intervention: Device: Continuous Positive Airway Pressure device (Resmed, Swift, Mirage)
Sponsors: American Lung Association Asthma Clinical Research Centers; American Lung Association Asthma Clinical Research Centers; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2013 - Conditions: Acquired Brain Injury; Stroke; Hemispatial Neglect
Interventions: Behavioral: Tonic and Phasic Attention Training; Behavioral: Active Comparator
Sponsors: Posit Science Corporation; Posit Science Corporation
Recruiting - verified May 2013 - Condition: Chronic Renal Failure Requiring Hemodialysis
Intervention: Biological: Epoetin Hospira
Sponsors: Hospira, Inc.; Hospira, Inc.
Recruiting - verified May 2013 - Condition: Chronic Renal Failure Requiring Hemodialysis
Intervention: Biological: Epoetin Hospira
Sponsors: Hospira, Inc.; Hospira, Inc.
Recruiting - verified May 2013 - Condition: Osteonecrosis of the Jaw (ONJ)
Intervention:
Sponsors: Amgen; Amgen
Recruiting - verified April 2013 - Conditions: Age Related Macular Degeneration; Macular Degeneration; AMD
Intervention: Drug: HuCNS-SC cells
Sponsors: StemCells, Inc.; StemCells, Inc.
Recruiting - verified May 2013 - Condition: Brain Tumor
Intervention: Other: Interoperative Optical Imaging and Spectroscopy
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Narcolepsy
Intervention: Drug: Armodafinil
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified April 2013 - Condition: Hypercholesterolemia
Interventions: Drug: SAR236553 (REGN727); Other: placebo
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified May 2013 - Condition: Measles, Mumps and Rubella Diseases
Interventions: Biological: Priorix®; Biological: Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine (also known as M-M-R Vax Pro™); Biological: Kinrix®; Biological: Varivax®
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013 - Conditions: Type 2 Diabetes; Chronic Kidney Disease
Interventions: Drug: Dulaglutide; Drug: Insulin glargine; Drug: Insulin lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Sinusitis
Intervention: Device: SinuSys Dilation System
Sponsors: SinuSys Corporation; SinuSys Corporation
Recruiting - verified May 2013 - Condition: Ulcerative Colitis
Interventions: Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Osteoarthritis of the Knee
Interventions: Drug: NKTR-181; Drug: Placebo
Sponsors: Nektar Therapeutics; Nektar Therapeutics
Recruiting - verified May 2013 - Condition: Type II Diabetes
Interventions: Drug: Placebo; Drug: Sitagliptin; Drug: LEZ763
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Osteoarthritis
Intervention: Device: Synvisc-One (G-F 20)
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified April 2013 - Condition: Hypercholesterolaemia
Interventions: Drug: SAR236553 (REGN727); Drug: placebo
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified May 2013 - Condition: Schizophrenia
Interventions: Drug: Asenapine; Drug: Placebo Asenapine; Drug: Olanzapine; Drug: Placebo Olanzapine
Sponsors: Merck; Merck
Recruiting - verified April 2013 - Condition: Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.
Intervention: Biological: Darbepoetin alfa
Sponsors: Amgen; Amgen
Recruiting - verified April 2013 - Condition: Breast Cancer
Intervention:
Sponsors: Genentech; Genentech
Recruiting - verified May 2013 - Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: BIBF 1120
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Cancer
Intervention: Biological: WT2725
Sponsors: Sunovion; Sunovion; Dainippon Sumitomo Pharma
Recruiting - verified April 2013 - Condition: HIV Infections
Interventions: Drug: Lamivudine/zidovudine; Drug: Lopinavir/ritonavir; Drug: Efavirenz; Drug: Raltegravir
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2013 - Condition: Cystic Fibrosis
Interventions: Drug: Ivacaftor; Drug: Placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated; Cystic Fibrosis Foundation
Recruiting - verified April 2013 - Conditions: Perioperative/Postoperative Complications; Prostate Cancer
Interventions: Procedure: robot-assisted laparoscopic surgery; Other: questionnaire administration; Other: intraoperative complication management/prevention
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Stomach Neoplasms; Esophageal Neoplasms; Metastatic Gastric Cancer; Mutated PI3KCA Protein; Overexpressed HER2 Protein;
Interventions: Drug: AUY922; Drug: BYL719
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Coronary Artery Disease (CAD)
Intervention: Drug: Regadenoson
Sponsors: Astellas Pharma Inc; Astellas Pharma Global Development, Inc.
Recruiting - verified May 2013 - Condition: Emphysema
Intervention: Device: PneumRx RePneu Lung Volume Reduction Coil (RePneu LVRC) System
Sponsors: PneumRx, Inc.; PneumRx, Inc.
Recruiting - verified December 2012 - Condition: Postmenopausal Women With Osteoporosis
Interventions: Drug: AMG 785; Drug: Alendronate
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Condition: Arthritis, Rheumatoid
Interventions: Drug: Placebo; Drug: Placebo; Drug: Sirukumab; Drug: Sirukumab; Drug: Sirukumab
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013 - Conditions: Prostate Cancer; Castration Resistant Prostate Cancer; Pain; Prostatic Neoplasms
Interventions: Drug: cabozantinib; Drug: prednisone
Sponsors: Exelixis; Exelixis
Recruiting - verified May 2013 - Condition: Arthritis, Rheumatoid
Interventions: Drug: Placebo; Drug: Placebo; Drug: Sirukumab; Drug: Sirukumab; Drug: Sirukumab
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013 - Condition: Chronic Kidney Disease
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified May 2013 - Condition: Female Orgasmic Disorder
Interventions: Drug: Placebo; Drug: Low dose TBS-2; Drug: Medium dose TBS-2; Drug: High dose TBS-2
Sponsors: Trimel Biopharma SRL; Trimel Biopharma SRL
Recruiting - verified May 2013 - Condition: Acute Kidney Injury
Interventions: Biological: AC607; Biological: Vehicle Only
Sponsors: AlloCure Inc.; AlloCure Inc.
Recruiting - verified May 2013 - Condition: Heart Failure
Intervention: Device: Automated Medication Dispensing Device
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified April 2013 - Condition: Waldenstrom's Macroglobulinemia
Intervention: Drug: PCI-32765
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Recruiting - verified April 2013 - Condition: Multiple Myeloma
Interventions: Drug: Placebo; Drug: Dexamethasone; Drug: Bortezomib; Biological: Tabalumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: Ibrutinib; Drug: Bendamustine hydrochloride; Drug: Rituximab; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Recruiting - verified May 2013 - Conditions: cUTI; Complicated Urinary Tract Infection; Acute Pyelonephritis
Interventions: Drug: CAZ-AVI; Drug: Doripenem; Drug: Either switch to oral therapy : 500 mg of Ciprofloxacin (oral); Drug: or switch to oral therapy : 800 mg/160 mg of sulfamethoxazole/trimethoprim
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Recruiting - verified May 2013 - Condition: Alzheimer's Disease
Interventions: Drug: E2609; Drug: Placebo for E2609
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2013 - Condition: Diabetic Nephropathy
Interventions: Drug: Repository Corticotropin Injection; Drug: Placebo
Sponsors: Questcor Pharmaceuticals, Inc.; Questcor Pharmaceuticals, Inc.
Recruiting - verified May 2013 - Condition: Breast Cancer
Interventions: Drug: BKM120 Matching placebo; Drug: Fulvestrant; Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Neuroblastoma
Interventions: Drug: MLN8237; Drug: Irinotecan; Drug: Temozolomide
Sponsors: New Approaches to Neuroblastoma Therapy Consortium; New Approaches to Neuroblastoma Therapy Consortium
Recruiting - verified April 2013 - Condition: Melanoma
Interventions: Drug: Dabrafenib; Drug: Vemurafenib; Drug: Trametinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Psoriasis
Interventions: Drug: 80 mg ixekizumab Dosing Regimen; Drug: 50 mg etanercept; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Conditions: Aneuploidy; Down Syndrome; Noninvasive Prenatal Screening
Intervention: Device: SEQureDx Trisomy Test
Sponsors: Sequenom, Inc.; Sequenom, Inc.
Recruiting - verified May 2013 - Condition: Eisenmenger
Intervention: Other: Management
Sponsors: Actelion; Actelion
Recruiting - verified May 2013 - Condition: Vulvar Cancer
Interventions: Drug: cisplatin; Drug: gemcitabine hydrochloride; Procedure: biopsy; Procedure: therapeutic conventional surgery; Radiation: intensity-modulated radiation therapy
Sponsors: Gynecologic Oncology Group; Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Sarcoma
Interventions: Drug: RO5045337; Drug: doxorubicin
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Hypercholesterolemia
Interventions: Drug: PBO; Drug: 200mg PF-04950615 (RN316); Drug: 300mg PF-04950615 (RN316); Drug: PBO; Drug: PF-04950615; Drug: PF-04950615; Drug: PF-04950615
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Chronic Pain
Interventions: Device: SR-electrical stimulation (Bioness); Device: Control ES and pain medication during first 3 months (Bioness)
Sponsors: Bioness Inc; Bioness Inc
Recruiting - verified April 2013 - Condition: Solid Tumors
Interventions: Drug: Iniparib (SAR240550/BSI-201); Drug: Carboplatin; Drug: Doxorubicin HCL liposome injection; Drug: Gemcitabine; Drug: Irinotecan; Drug: Paclitaxel; Drug: Topotecan
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013 - Condition: Neuroblastoma
Interventions: Biological: ch14.18 -NCI; Biological: ch14.18-UTC; Biological: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF); Biological: Aldesleukin (IL-2); Drug: Isotretinoin
Sponsors: United Therapeutics; United Therapeutics
Recruiting - verified April 2013 - Condition: Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Interventions: Drug: CAZ-AVI; Drug: Doripenem; Drug: Either switch to oral therapy: 500 mg of Ciprofloxacin (oral); Drug: or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Recruiting - verified May 2013 - Condition: Clostridium Difficile-associated Diarrhea
Intervention: Drug: fidaxomicin
Sponsors: Optimer Pharmaceuticals; Optimer Pharmaceuticals
Recruiting - verified April 2013 - Condition: Neuroblastoma
Intervention:
Sponsors: New Approaches to Neuroblastoma Therapy Consortium; New Approaches to Neuroblastoma Therapy Consortium
Recruiting - verified April 2013 - Condition: Neoplasm Malignant
Interventions: Drug: SAR245408; Drug: SAR245409
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013 - Condition: Chemotherapy-Induced Nausea and Vomiting
Interventions: Drug: Fosaprepitant dimeglumine; Drug: Fosaprepitant Placebo; Drug: Dexamethasone; Drug: Ondansetron; Drug: Dexamethasone Placebo; Drug: Ondansetron Placebo; Drug: Rescue Therapy
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Severe Aortic Stenosis
Interventions: Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Procedure: Surgical Aortic Valve Replacement (SAVR)
Sponsors: Medtronic Cardiovascular; Medtronic Cardiovascular
Recruiting - verified May 2013 - Condition: Anaemia
Interventions: Drug: GSK1278863; Drug: rhEPO
Sponsors: GlaxoSmithKline; GlaxoSmithKline; PPD
Recruiting - verified May 2013 - Conditions: Guillain-Barré Syndrome; Miller Fisher Syndrome
Intervention:
Sponsors: Erasmus Medical Center; Erasmus Medical Center
Recruiting - verified May 2013 - Condition: Anaemia
Interventions: Drug: GSK1278863; Other: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline; PPD
Recruiting - verified April 2013 - Conditions: Advanced Renal Cell Carcinoma; Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma
Interventions: Drug: Standard Treatment; Biological: AGS-003
Sponsors: Argos Therapeutics; Argos Therapeutics
Recruiting - verified May 2013 - Condition: Glioblastoma
Interventions: Drug: LY2157299 monohydrate; Drug: Lomustine; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Age-Related Maculopathy
Interventions: Biological: RN6G; Biological: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Asthma
Interventions: Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4; Other: Placebo DPI; Drug: Flovent Diskus 250 mcg
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified April 2013 - Condition: Prostate Cancer
Interventions: Drug: cabazitaxel, prednisone, custirsen sodium; Drug: cabazitaxel, prednisone
Sponsors: OncoGenex Technologies; OncoGenex Technologies; Teva Pharmaceutical Industries
Recruiting - verified May 2013 - Condition: Type 2 Diabetes
Interventions: Drug: Mesenchymal Precursor Cells (MPCs); Drug: Mesenchymal Precursor Cells (MPCs); Drug: Mesenchymal Precursor Cells (MPCs)
Sponsors: Mesoblast, Ltd.; Mesoblast, Ltd.
Recruiting - verified April 2013 - Condition: Huntington's Disease
Intervention:
Sponsors: CHDI Foundation, Inc.; CHDI Foundation, Inc.
Recruiting - verified May 2013 - Condition: Smoking Cessation
Interventions: Drug: placebo; Drug: varenicline tartrate; Drug: bupropion hydrochloride; Drug: Nicotine Replacement Therapy Patch
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: BKM120 matching placebo; Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Lixisenatide (AVE0010); Drug: Placebo
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013 - Conditions: Chronic Pain; Low Back Pain; Analgesia
Interventions: Drug: ALO-02; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Colorectal Cancer Metastatic
Interventions: Drug: AFLIBERCEPT AVE0005; Drug: FOLFIRI
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified May 2013 - Condition: Rheumatoid Arthritis (RA)
Interventions: Drug: MK-8457 100 mg BID; Drug: MK-8457 100 mg QD; Drug: Dose-Matched Placebo; Drug: MK-8457 200 mg QD; Drug: MK-8457 25 mg QD; Drug: MK-8457 25 mg BID
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Advanced Cancer
Interventions: Drug: crizotinib; Drug: crizotinib; Drug: crizotinib; Drug: crizotinib; Drug: crizotinib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Psoriasis
Interventions: Drug: STF 115469 Foam; Drug: Vehicle Foam
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Conditions: Anal Cancer; Cervical Cancer; Lung Cancer; Lymphoma; Nonneoplastic Condition
Interventions: Genetic: DNA analysis; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: polymorphism analysis; Other: biologic sample preservation procedure; Other: flow cytometry; Other: laboratory biomarker analysis; Other: medical chart review
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Myopathic Symptoms
Interventions: Drug: Ergocalciferol; Drug: Placebo
Sponsors: Cedars-Sinai Medical Center; Cedars-Sinai Medical Center
Recruiting - verified May 2013 - Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib plus dexamethasone; Drug: Velcade plus dexamethasone
Sponsors: Onyx Pharmaceuticals; Onyx Pharmaceuticals
Recruiting - verified May 2013 - Condition: Hemophilia A
Intervention: Biological: BAY94-9027
Sponsors: Bayer; Bayer
Recruiting - verified April 2013 - Condition: Schizophrenia
Intervention: Drug: Lurasidone
Sponsors: Sunovion; Sunovion
Recruiting - verified May 2013 - Condition: Myelodysplastic Syndrome
Interventions: Drug: Oral Azacitidine; Drug: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2013 - Condition: Bipolar I Disorder
Interventions: Drug: Intramuscular (IM) Depot Aripiprazole; Drug: Intramuscular (IM) Depot Placebo
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.; H. Lundbeck A/S
Recruiting - verified May 2013 - Conditions: Relapsed Multiple Myeloma; Refractory Multiple Myeloma
Interventions: Drug: MLN9708 + Lenalidomide + Dexamethasone; Drug: Placebo + Lenalidomide + Dexamethasone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2013 - Condition: Alzheimer's Disease
Interventions: Drug: LY2886721; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Tuberculosis
Interventions: Drug: PA-824; Drug: Efavirenz (EFV); Drug: Lopinavir/Ritonavir (LPV/r); Drug: Rifampin (RIF)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin/metformin XR; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified April 2013 - Condition: Asthma
Interventions: Drug: Fluticasone Furoate; Drug: Fluticasone Propionate; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013 - Condition: Urinary Bladder, Neurogenic
Interventions: Drug: Fesoterodine 4 mg; Drug: Fesoterodine 8 mg; Drug: Oxybutynin; Drug: Fesoterodine
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Lupus Arthritis, Systemic Lupus Erythematosus
Interventions: Drug: AMG 557 210 mg; Drug: 210 mg Matching Placebo; Drug: AMG 557 140 mg; Drug: 140 mg Matching Placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2013 - Condition: Myocardial Ischemia
Interventions: Device: ADRCs processed by the Celution System; Device: Placebo Comparator: Lactated Ringer's and Subject's Blood
Sponsors: Cytori Therapeutics; Cytori Therapeutics
Recruiting - verified April 2013 - Condition: Diabetic Foot Ulcers
Interventions: Other: Tissue; Other: Control
Sponsors: Osiris Therapeutics; Osiris Therapeutics
Recruiting - verified May 2013 - Condition: Arthritis, Rheumatoid
Interventions: Drug: ASP015K; Drug: Placebo
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified May 2013 - Condition: Major Depressive Disorder, Recurrent
Interventions: Drug: MK-6096; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Bicompartmental Osteoarthritis
Intervention: Device: iDuo G2
Sponsors: ConforMIS, Inc.; ConforMIS, Inc.
Recruiting - verified April 2013 - Condition: Parkinson's Disease
Intervention: Drug: nicotine transdermal patch
Sponsors: University of Vermont; James BOYD MD; Michael J. Fox Foundation for Parkinson's Research
Recruiting - verified May 2013 - Condition: Sjögren's Syndrome
Interventions: Biological: Baminercept; Other: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013 - Condition: Diffuse Large Cell Lymphoma Relapsed/Refractory
Interventions: Drug: Ofatumumab; Drug: Etoposide; Drug: Cytarabine
Sponsors: University of California, San Francisco; C. Babis Andreadis; University of California, San Francisco; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Psoriasis
Interventions: Drug: Ustekinumab 45 mg; Drug: Ustekinumab 90 mg; Drug: Placebo
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified May 2013 - Condition: Irritable Bowel Syndrome
Interventions: Drug: JNJ-27018966; Other: Placebo Comparator
Sponsors: Furiex Pharmaceuticals, Inc; Furiex Pharmaceuticals, Inc
Recruiting - verified May 2013 - Condition: Irritable Bowel Syndrome
Interventions: Drug: JNJ-27018966; Drug: Placebo
Sponsors: Furiex Pharmaceuticals, Inc; Furiex Pharmaceuticals, Inc
Recruiting - verified May 2013 - Condition: Juvenile Idiopathic Arthritis (JIA)
Intervention: Drug: Certolizumab Pegol (CZP)
Sponsors: UCB, Inc.; UCB BIOSCIENCES GmbH
Recruiting - verified May 2013 - Conditions: Type 2 Diabetes Mellitus; Renal Impairment
Interventions: Drug: LX4211; Drug: LX4211 Placebo
Sponsors: Lexicon Pharmaceuticals; Lexicon Pharmaceuticals
Recruiting - verified May 2013 - Condition: Attention-deficit/Hyperactivity Disorder
Interventions: Drug: Lisdexamfetamine dimesylate; Drug: Methylphenidate Hydrochloride; Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013 - Condition: Attention-deficit/Hyperactivity Disorder
Interventions: Drug: Lisdexamfetamine dimesylate; Drug: Methylphenidate Hydrochloride; Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013 - Condition: Post-traumatic Stress Disorder
Interventions: Drug: Propranolol Hydrochloride; Other: Placebo
Sponsors: University of California, San Francisco; University of California, San Francisco; Department of Defense; Northern California Institute of Research and Education
Recruiting - verified May 2013 - Conditions: Carcinoma, Non-Small-Cell Lung; Non-Small Cell Lung Cancer
Interventions: Drug: CC-223; Drug: Erlotinib; Drug: Oral azacitidine concurrent; Drug: oral azacitidine sequential
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2013 - Conditions: Trisomy 13; Trisomy 18; Trisomy 21; Aneuploidy
Intervention: Procedure: Blood Draw
Sponsors: Natera, Inc.; Natera, Inc.; Columbia University; George Washington University; National Institutes of Health (NIH)
Recruiting - verified May 2013 - Condition: Hepatitis C, Chronic
Interventions: Biological: peginterferon alfa-2a; Drug: ribavirin; Drug: boceprevir
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Schizophrenia
Interventions: Drug: AMG 747; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: PH-797804; Drug: PH-797804; Drug: PH-797804; Drug: PH-797804; Drug: PH-797804; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Schizophrenia
Interventions: Drug: AMG 747; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Condition: Irritable Bowel Syndrome With Diarrhea
Interventions: Drug: rifaximin; Drug: placebo
Sponsors: Salix Pharmaceuticals; Salix Pharmaceuticals
Recruiting - verified January 2013 - Condition: Juvenile Idiopathic Arthritis
Interventions: Behavioral: Web-based coping skills training; Behavioral: Online disease education
Sponsors: Children's Mercy Hospital Kansas City; Children's Mercy Hospital Kansas City; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified May 2013 - Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: liraglutide; Drug: placebo; Drug: metformin
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013 - Condition: Colorectal Neoplasms
Intervention: Drug: Regorafenib (BAY73-4506)
Sponsors: Bayer; Bayer
Available - verified May 2013 - Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide; Drug: Pegylated Liposomal Doxorubicin (PLD); Drug: Dexamethasone
Sponsors: Oncotherapeutics; Oncotherapeutics; Celgene Corporation
Recruiting - verified August 2012 - Condition: Relapsed or Refractory Hodgkin Lymphoma
Interventions: Drug: Phase 1, Cohort 1; Drug: Phase 1, Cohort 2; Drug: Phase 1, Cohort 3; Drug: Phase 1, Cohort 4; Drug: Phase 2
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013 - Conditions: Cardiac Surgery; Erythrocyte Transfusion
Intervention:
Sponsors: New England Research Institutes; New England Research Institutes; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2013 - Conditions: Down Syndrome; Fetal Aneuploidy
Intervention:
Sponsors: Sequenom, Inc.; Sequenom, Inc.
Recruiting - verified May 2013 - Condition: Advanced Parkinson's Disease
Interventions: Drug: Rotigotine; Drug: Placebo
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2013 - Condition: Neoplasms
Interventions: Drug: 5-Fluoro-2-Deoxycytidine; Drug: Tetrahydrouridine
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2012 - Condition: Bone Mineral Density
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco; Mayo Clinic
Recruiting - verified May 2013 - Conditions: Psoriasis; Cardiovascular Disease
Interventions: Drug: Adalimumab (Humira); Drug: Placebo Injection; Other: NB-UVB phototherapy
Sponsors: University of Pennsylvania; University of Pennsylvania
Recruiting - verified April 2013 - Conditions: Advanced Cancers; DLBCL; Lymphoma
Intervention: Drug: ISIS-STAT3Rx
Sponsors: Isis Pharmaceuticals; Isis Pharmaceuticals; AstraZeneca
Recruiting - verified April 2013 - Condition: Sclerosis, Systemic
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: Placebo; Drug: tocilizumab [RoActemra/Actemra]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Conditions: Neovascular Age-elated Macular Degeneration (Wet AMD); Exudative Macular Degeneration
Interventions: Drug: LFG316; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Schizophrenia
Interventions: Drug: PPM3 175 mg eq.; Drug: PPM3 263 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: Placebo (20% Intralipid emulsion)
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2013 - Conditions: Geographic Atrophy; Age-related Macular Degeneration
Interventions: Drug: LFG316; Drug: Sham
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Interventions: Biological: PF-05280586; Biological: MabThera; Biological: Rituxan
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected PatientsCondition: Hepatitis C, Chronic
Interventions: Drug: tenofovir; Drug: midazolam; Drug: BI 201335; Drug: caffeine; Drug: tolbutamide; Drug: tolbutamide; Drug: midazolam; Drug: caffeine; Drug: pegylated interferon; Drug: BI 201335; Drug: BI 201335; Drug: BI 207127; Drug: BI 207127; Drug: ribavirin; Drug: ribavirin; Drug: ribavirin; Drug: BI 201335; Drug: BI 207127; Drug: ribavirin; Drug: pegylated interferon; Drug: caffeine; Drug: tolbutamide; Drug: BI 207127; Drug: ribavirin; Drug: midazolam; Drug: BI 201335; Drug: BI 207127
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium + olodaterol (high dose); Drug: tiotropium+olodaterol; Drug: placebo to tiotropium+olodaterol
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: afatinib; Drug: erlotinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Hematopoietic Neoplasm
Intervention: Drug: SAR302503
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013 - Conditions: Metastatic Castration-resistant Prostate Cancer; Metastatic Breast Cancer
Interventions: Drug: Abiraterone acetate; Drug: Abiraterone acetate
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2013 - Condition: Prostatic Neoplasms
Intervention: Drug: Radium-223 dichloride (BAY88-8223)
Sponsors: Bayer; Bayer
Available - verified May 2013 - Condition: Fragile X Syndrome
Interventions: Drug: RO4917523; Drug: RO4917523; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX); Biological: Placebo + Methotrexate (MTX)
Sponsors: UCB, Inc.; UCB Pharma SA
Recruiting - verified April 2013 - Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX); Biological: Placebo + Methotrexate (MTX)
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified April 2013 - Conditions: Crohn's Disease; Fatigue
Interventions: Drug: L-carnitine; Other: Placebo
Sponsors: University of California, San Francisco; University of California, San Francisco
Not yet recruiting - verified May 2013 - Condition: Schizophrenia
Interventions: Drug: PP3M 175 mg eq.; Drug: PP3M 263 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: Placebo (20% Intralipid); Drug: PP1M 50 mg eq.; Drug: PP1M 75 mg eq.; Drug: PP1M 100 mg eq.; Drug: PP1M 150 mg eq.
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013 - Condition: Psoriasis
Intervention: Drug: etanercept
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Condition: Epithelial Ovarian Cancer
Interventions: Biological: Placebo Study Agent; Biological: Cvac
Sponsors: Prima BioMed Ltd; Prima BioMed Ltd
Recruiting - verified May 2013 - Condition: Malignant Melanoma
Intervention: Drug: vemurafenib
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Conditions: Prostate Cancer; Castration Resistant Prostate Cancer; Pain; Prostatic Neoplasms
Interventions: Drug: cabozantinib; Drug: mitoxantrone; Drug: prednisone
Sponsors: Exelixis; Exelixis
Recruiting - verified May 2013 - Condition: Well-differentiated Pancreatic Neuroendocrine Tumor
Intervention: Drug: sunitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Tophaceous Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2013 - Conditions: Metastatic Soft Tissue Sarcoma; Locally Advanced Soft Tissue Sarcoma; Unresectable Soft Tissue Sarcoma
Interventions: Drug: INNO-206; Drug: Doxorubicin
Sponsors: CytRx; CytRx
Recruiting - verified May 2013 - Condition: Atherosclerosis
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2013 - Condition: Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2013 - Conditions: Chronic Myocardial Ischemia; Refractory Angina Pectoris; (Advanced) Coronary Heart Disease
Interventions: Biological: Auto-CD34+ cells; Biological: Placebo: Diluent used to suspend Auto-CD34+ cells; Other: Standard of care
Sponsors: Baxter Healthcare Corporation; Baxter Healthcare Corporation
Recruiting - verified May 2013 - Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Hypercholesterolemia
Interventions: Other: placebo; Drug: SAR236553 (REGN727)
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified May 2013 - Condition: Liver Cancer
Interventions: Drug: RO5137382; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Conditions: Diffuse Large B-cell Lymphoma; Follicle Center Lymphoma
Intervention: Drug: Zevalin (ibritumomab tiuxetan)
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc
Recruiting - verified May 2013 - Conditions: Urinary Tract Infections; Pyelonephritis
Interventions: Drug: MK-7655 250 mg with imipenem/cilastatin; Drug: MK-7655 125 mg with imipenem/cilastatin; Drug: imipenem/cilastatin 500 mg; Drug: Placebo to MK-7655
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Pancreatic Cancer
Interventions: Drug: LY2495655; Drug: Gemcitabine; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Corneal Opacity
Interventions: Procedure: OCT guided laser-assisted lamellar anterior keratoplasty (LALAK); Procedure: Penetrating Keratoplasty (KP)
Sponsors: Oregon Health and Science University; Oregon Health and Science University; National Institutes of Health (NIH); National Eye Institute (NEI)
Recruiting - verified May 2013 - Condition: HIV Infections
Intervention: Drug: Etravirine (ETR)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013 - Condition: Asthma
Interventions: Drug: Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg; Drug: Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcg; Drug: Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg; Drug: Mometasone Furoate (MF) Dry Powder Inhaler (DPI), 100 mcg; Drug: Placebo Metered Dose Inhaler (MDI); Drug: Placebo Dry Powder Inhaler (DPI)
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (CZP + MTX); Biological: Adalimumab + Methotrexate (ADA + MTX)
Sponsors: UCB, Inc.; UCB Pharma SA
Recruiting - verified May 2013 - Condition: Complicated Intra-Abdominal Infection
Interventions: Drug: CAZ-AVI; Drug: Metronidazole; Drug: Meropenem
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Recruiting - verified April 2013 - Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component; Recurrent Glioblastoma; Relapsed Glioblastoma
Interventions: Drug: Bevacizumab; Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2013 - Condition: Ligneous Conjunctivitis
Intervention: Biological: Human Plasminogen
Sponsors: Kedrion S.p.A.; Kedrion S.p.A.
Recruiting - verified May 2013 - Condition: BRAF Mutant Metastatic Melanoma
Intervention: Drug: BKM120 Combined with Vemurafenib (PLX4032)
Sponsors: University of California, San Francisco; University of California, San Francisco; Novartis
Recruiting - verified May 2013 - Condition: Complicated Intra-Abdominal Infection
Interventions: Drug: CAZ-AVI; Drug: Metronidazole; Drug: Meropenem
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Recruiting - verified May 2013 - Condition: Restless Legs Syndrome
Intervention: Drug: Rotigotine
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2013 - Condition: Restless Legs Syndrome
Intervention: Drug: Rotigotine
Sponsors: UCB, Inc.; UCB BIOSCIENCES, Inc.
Recruiting - verified May 2013 - Condition: Metastatic Pancreatic Cancer
Interventions: Drug: MM-398; Drug: 5 Fluorouracil; Drug: Leucovorin
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals
Recruiting - verified April 2013 - Condition: Irritable Bowel Syndrome
Interventions: Drug: 250 mg LX1033 tablets; Drug: Placebo tablet
Sponsors: Lexicon Pharmaceuticals; Lexicon Pharmaceuticals
Recruiting - verified April 2013 - Condition: Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2013 - Condition: Alzheimer's Disease
Interventions: Drug: BMS-241027; Drug: BMS-241027; Drug: BMS-241027; Drug: Placebo matching BMS-241027
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013 - Condition: ST Segment Elevation Myocardial Infarction
Interventions: Biological: AMR-001; Other: placebo
Sponsors: Amorcyte, Inc.; Amorcyte, Inc.
Recruiting - verified February 2013 - Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: trastuzumab; Drug: Aromatase Inhibitor; Drug: Induction Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Hepatitis B, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: peginterferon alfa-2a [Pegasys]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Conditions: Metastatic Colorectal Cancer; Colorectal Cancer
Interventions: Drug: MORAb-004; Drug: Placebo
Sponsors: Morphotek; Morphotek
Recruiting - verified May 2013 - Condition: Cervical Dystonia
Intervention: Biological: Xeomin®
Sponsors: Merz Pharmaceuticals, LLC; Merz Pharmaceuticals, LLC
Recruiting - verified April 2013 - Condition: Ovarian Cancer Recurrent
Interventions: Drug: EP-100; Drug: Paclitaxel
Sponsors: Esperance Pharmaceuticals Inc; Esperance Pharmaceuticals Inc
Recruiting - verified May 2013 - Condition: Ovarian Epithelial Carcinoma
Intervention: Drug: PD0332991
Sponsors: Jonsson Comprehensive Cancer Center; Jonsson Comprehensive Cancer Center
Recruiting - verified May 2013 - Conditions: HIV Infections; Hepatitis C
Interventions: Drug: Pegylated-Interferon Alfa 2b (PEG-IFN); Drug: Ribavirin (RBV); Drug: Boceprevir (BOC)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013 - Condition: Colorectal Cancer Metastatic
Intervention: Device: TheraSphere
Sponsors: Nordion (Canada) Inc.; Nordion (Canada) Inc.
Recruiting - verified May 2013 - Condition: Lupus Nephritis
Interventions: Drug: BIIB023; Drug: Placebo
Sponsors: Biogen Idec; Biogen Idec; Biogen Idec Australia Pty Ltd; Biogen Idec Research Ltd.; Biogen Idec MA Inc.
Recruiting - verified April 2013 - Conditions: Congenital Bleeding Disorder; Haemophilia A
Intervention: Drug: NNC 0129-0000-1003
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified April 2013 - Condition: Asthma
Interventions: Drug: Placebo; Drug: Flovent Diskus; Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; PPD
Recruiting - verified April 2013 - Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: Temozolomide; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2013 - Condition: HER2 Negative Breast Cancer
Interventions: Biological: NeuVax vaccine; Biological: Leukine (sargramostim, GM-CSF) and water for injection
Sponsors: Galena Biopharma, Inc.; Galena Biopharma, Inc.
Recruiting - verified May 2013 - Condition: Hemophilia A
Intervention: Biological: Recombinant Factor VIII (rFVIII)
Sponsors: CSL Behring; CSL Behring
Recruiting - verified May 2013 - Condition: Stage IV Pancreatic Cancer
Interventions: Drug: Gemcitabine; Drug: nab-paclitaxel; Drug: FOLFIRINOX; Genetic: Immunohistochemistry (IHC) Analysis; Drug: Metformin
Sponsors: Pancreatic Cancer Research Team; Pancreatic Cancer Research Team
Recruiting - verified September 2012 - Conditions: Hypercholesterolemia; Coronary Heart Disease
Interventions: Drug: mipomersen sodium 200 mg; Drug: Placebo; Drug: mipomersen sodium 70 mg
Sponsors: Genzyme; Genzyme
Recruiting - verified May 2013 - Conditions: Anticoagulation; Left Ventricular Assist Device
Intervention:
Sponsors: Thoratec Europe Ltd; Thoratec Europe Ltd; Thoratec Corporation
Recruiting - verified May 2013 - Condition: Diabetic Peripheral Neuropathy
Interventions: Drug: Pregabalin; Other: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Conditions: Heart Failure; Cardiac Failure; Acute Decompensated Heart Failure (ADHF)
Interventions: Device: Isolated veno-venous ultrafiltration (AQ); Drug: IV Loop Diuretics (LD)
Sponsors: Gambro Renal Products, Inc.; Gambro Renal Products, Inc.; Gambro UF Solutions, Inc.
Recruiting - verified May 2013 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Metformin; Drug: Sitagliptin / Metformin; Drug: Placebo to Metformin; Drug: Placebo to Sitagliptin / Metformin
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Asthma
Interventions: Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg; Drug: Mometasone Furoate/Formoterol MDI 200/5 mcg; Drug: Mometasone Furoate MDI 100 mcg; Drug: Mometasone Furoate MDI 200 mcg; Drug: Albuterol 90 mcg /salbutamol 100 mcg HFA MDI; Drug: Prednisone/prednisolone
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Colorectal Cancer
Interventions: Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: Placebo; Drug: FOLFIRI
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Condition: Cutaneous Lupus Erythematosus
Interventions: Drug: PD-0360324; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Acute Alcoholic Hepatitis
Interventions: Biological: ELAD treatment; Other: Standard of care (Control)
Sponsors: Vital Therapies, Inc.; Vital Therapies, Inc.
Recruiting - verified April 2013 - Conditions: Glioblastoma Multiforme; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Oligoastrocytoma
Intervention: Biological: Toca 511
Sponsors: Tocagen Inc.; Tocagen Inc.
Recruiting - verified July 2012 - Conditions: Chronic Kidney Disease; Chronic Renal Failure
Interventions: Biological: Epoetin Hospira; Biological: Epogen (Amgen)
Sponsors: Hospira, Inc.; Hospira, Inc.
Recruiting - verified May 2013 - Conditions: Chronic Renal Failure; Chronic Kidney Disease
Interventions: Biological: Epoetin Hospira; Biological: Epogen Amgen
Sponsors: Hospira, Inc.; Hospira, Inc.
Recruiting - verified May 2013 - Conditions: Systemic Sclerosis; Ulcers
Interventions: Drug: macitentan 3mg; Drug: macitentan 10mg; Drug: placebo
Sponsors: Actelion; Actelion
Recruiting - verified May 2013 - Condition: Neuropathic Pain
Interventions: Drug: SAR292833; Drug: placebo
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013 - Conditions: Stroke; Atrial Fibrillation
Intervention:
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Conditions: Intracranial Aneurysms; Peripheral Aneurysms
Intervention: Device: PC 400 coils (Penumbra )
Sponsors: Penumbra Inc.; Penumbra Inc.
Recruiting - verified May 2013 - Condition: Crohn's Disease
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: Acute Myeloid Leukemia; Advanced Myelodysplastic Syndrome
Interventions: Drug: Panobinostat; Drug: Cytarabine; Drug: Daunorubicin
Sponsors: University of California, San Francisco; University of California, San Francisco; Novartis
Recruiting - verified May 2013 - Conditions: Acute Lymphoid Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Multiple Myeloma; Solid Tumors
Interventions: Drug: brentuximab vedotin; Drug: brentuximab vedotin
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified May 2013 - Condition: Ulcerative Colitis
Interventions: Drug: tofacitinib; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Ulcerative Colitis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Ulcerative Colitis
Interventions: Drug: Placebo; Drug: CP690,550; Drug: CP690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Ulcerative Colitis
Interventions: Drug: tofacitinib; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Depression Disorder, Major
Interventions: Drug: RO4995819; Drug: RO4995819; Drug: RO4995819; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Non Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dacomitinib Plus Blinded Doxycycline or Placebo; Drug: Dacomitinib Plus Probiotic Plus Topical Alclometasone cream; Drug: Dacomitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: Malignant Solid Tumour; Breast Cancer; Ovarian Cancer; Colorectal Cancer
Intervention: Drug: NKTR-102
Sponsors: Nektar Therapeutics; Nektar Therapeutics
Available - verified April 2013 - Condition: Juvenile Idiopathic Arthritis, Rheumatoid Arthritis
Intervention: Drug: Tocilizumab [RoActemra/Actemra]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Paroxysmal Atrial Fibrillation
Interventions: Device: EAS-AC (HeartLight); Procedure: Control Arm Ablation
Sponsors: CardioFocus; CardioFocus
Recruiting - verified April 2013 - Condition: Painful Diabetic Peripheral Neuropathy
Interventions: Drug: pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Condition: Epilepsy, Partial Seizures
Intervention: Drug: Pregabalin
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Condition: Ulcerative Colitis
Interventions: Drug: 500 mg LX1606 QD; Drug: 500 mg LX1606 TID; Drug: Placebo
Sponsors: Lexicon Pharmaceuticals; Lexicon Pharmaceuticals
Recruiting - verified May 2013 - Condition: Smoking Cessation
Interventions: Drug: Placebo; Drug: varenicline tartrate; Drug: bupropion hydrochloride; Drug: Nicotine Replacement Therapy Patch
Sponsors: Pfizer; Pfizer; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Crohn's Disease
Intervention: Drug: Entocort
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified May 2013 - Conditions: Pulmonary Arterial Hypertension; Pulmonary Hypertension
Interventions: Drug: Nitric Oxide; Other: Placebo; Drug: Nitric Oxide
Sponsors: INO Therapeutics; INO Therapeutics
Recruiting - verified May 2013 - Condition: Heart Failure
Interventions: Device: HM II (HeartMate II LVAD); Drug: OMM (Optimal Medical Management)
Sponsors: Thoratec Corporation; Thoratec Corporation
Recruiting - verified May 2013 - Condition: Gastric Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: trastuzumab [Herceptin]; Drug: capecitabine; Drug: cisplatin
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Small Cell Lung Carcinoma
Interventions: Biological: Ipilimumab; Biological: Placebo matching Ipilimumab; Drug: Etoposide; Drug: Cisplatin; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013 - Condition: Pulmonary Emphysema
Interventions: Device: Treatment plus Optimal Medical Therapy; Other: Optimal Medical Therapy
Sponsors: Aeris Therapeutics; Aeris Therapeutics
Recruiting - verified May 2013 - Conditions: Sudden Cardiac Death; Ventricular Fibrillation; Ventricular Tachycardia; Ventricular Dysfunction; Myocardial Ischemia
Intervention: Device: wearable defibrillator (LifeVest)
Sponsors: Zoll Medical Corporation; Zoll Medical Corporation
Recruiting - verified April 2013 - Conditions: Myocardial Infarction; Ventricular Dysfunction; Sudden Death; Ventricular Tachycardia; Ventricular Fibrillation
Intervention: Device: wearable defibrillator
Sponsors: University of California, San Francisco; University of California, San Francisco; Zoll Medical Corporation
Recruiting - verified April 2013 - Condition: Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions: Drug: MEDI-551; Drug: Rituximab; Drug: ICE; Drug: DHAP; Procedure: Autologous Stem Cell Transplant (ASCT)
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified May 2013 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: Paclitaxel; Drug: AMG 386 Placebo; Drug: Carboplatin
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Conditions: Idiopathic Thrombocytopenic Purpura; Thrombocytopenia; Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP); Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP); Thrombocytopenic Purpura
Interventions: Drug: romiplostim; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Conditions: Vaccines; Meningococcal Vaccines
Interventions: Biological: rLP2086 + MCV4 + Tdap; Biological: MCV4 + Tdap + saline; Biological: rLP2086 + saline
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: Vaccines; Meningococcal Vaccines
Interventions: Biological: rLP2086 and Gardasil; Biological: rLP2086; Biological: Gardasil
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Asthma
Interventions: Drug: Symbicort pMDI; Drug: Symbicort pMDI; Drug: budesonide pMDI; Drug: budesonide pMDI
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified May 2013 - Condition: Hypercholesterolemia
Interventions: Drug: AMG 145 and standard of care; Other: Standard of care
Sponsors: Amgen; Amgen
Recruiting - verified April 2013 - Conditions: Coronary Artery Disease; Angina Pectoris
Interventions: Drug: Ranolazine; Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Condition: Depression Disorder, Major
Interventions: Drug: RO4917523; Drug: RO4917523; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Conditions: Keratoconus; Corneal Ectasia
Interventions: Device: KXL System (15 mW/cm2); Device: KXL System (30 mW/cm2); Device: KXL System (45 mW/cm2); Drug: riboflavin ophthalmic solution
Sponsors: ACOS; ACOS
Recruiting - verified May 2013 - Condition: Non-small Cell Lung Cancer
Interventions: Biological: Nivolumab; Drug: Gemcitabine; Drug: Cisplatin; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Carboplatin; Drug: Bevacizumab; Drug: Erlotinib; Biological: Ipilimumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013 - Condition: Major Depressive Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate ); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013 - Condition: Major Depressive Disorder
Interventions: Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate ); Drug: Antidepressant + Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013 - Condition: Major Depressive Disorder
Interventions: Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg; Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg; Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg; Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg; Drug: Antidepressant + Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013 - Condition: Hepatitis C
Interventions: Other: Placebo; Biological: MVA-NSmut; Biological: AdCh3NSmut1
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013 - Condition: Breast Cancer
Interventions: Drug: fulvestrant; Drug: GDC-0941; Drug: GDC-0980; Drug: placebo; Drug: GDC-0941; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified May 2013 - Condition: Fibromyalgia
Interventions: Drug: Pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Condition: Hepatorenal Syndrome
Interventions: Drug: 5mg Ifetroban Injection; Drug: 15mg Ifetroban Injection; Drug: 50mg Ifetroban Injection; Drug: 150mg Ifetroban Injection; Other: 5% Dextrose in Water
Sponsors: Cumberland Pharmaceuticals; Cumberland Pharmaceuticals
Recruiting - verified April 2013 - Condition: Non-24-Hour Sleep-Wake Disorder
Intervention: Drug: tasimelteon
Sponsors: Vanda Pharmaceuticals; Vanda Pharmaceuticals
Recruiting - verified May 2013 - Condition: Asthma
Interventions: Drug: Placebo; Drug: Albuterol Spiromax®
Sponsors: Teva Pharmaceutical Industries; Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting - verified April 2013 - Condition: Schizophrenia
Intervention: Procedure: Computer-Based Cognitive Treatment
Sponsors: Posit Science Corporation; Cate Stasio; National Institute of Mental Health (NIMH)
Recruiting - verified May 2013 - Conditions: Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell
Interventions: Drug: brentuximab vedotin; Drug: rituximab
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified May 2013 - Condition: Down Syndrome
Interventions: Drug: RG1662; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Endometrial Neoplasms
Interventions: Drug: PF-05212384; Drug: PF-05212384; Drug: PF-05212384
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: Infection; Hypertension; Anesthesia; Pain; Reflux
Intervention: Drug: Ampicillin
Sponsors: Duke University; Daniel Benjamin; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); The EMMES Corporation
Recruiting - verified May 2013 - Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine [Kadcyla]; Drug: anti-cancer therapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Conditions: Post-Traumatic Stress Disorder; Brain Injuries, Traumatic
Intervention:
Sponsors: INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium; INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium; U.S. Army Medical Research and Materiel Command
Recruiting - verified April 2013 - Condition: Uncontrolled Hypertension
Intervention: Device: Renal denervation (Symplicity Catheter System)
Sponsors: Medtronic Vascular; Medtronic Vascular
Recruiting - verified May 2013 - Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: ocrelizumab; Drug: Rebif; Drug: ocrelizumab placebo; Drug: Rebif placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Conditions: Endothelial Dysfunction; Insulin Resistance; Metabolic Syndrome; Peripheral Arterial Disease
Interventions: Dietary Supplement: Fish Oil (Omega-3 Fatty Acids); Dietary Supplement: Fish Oil (Omega-3 Fatty Acids)
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified May 2013 - Condition: Traumatic Brain Injury
Intervention:
Sponsors: Emory University; Emory University; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2013 - Conditions: Tuberculosis; HIV Infections
Interventions: Drug: Rifapentine (RPT); Drug: Isoniazid (INH); Dietary Supplement: Pyridoxine (Vitamin B6)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013 - Conditions: Alzheimer Disease; Mild Cognitive Impairment; Neurodegenerative Diseases
Intervention: Drug: Florbetapir F 18
Sponsors: Avid Radiopharmaceuticals; Avid Radiopharmaceuticals
Recruiting - verified May 2013 - Condition: Depression, Bipolar
Interventions: Drug: Placebo; Drug: Cariprazine; Drug: Cariprazine; Drug: Cariprazine
Sponsors: Forest Laboratories; Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified April 2013 - Condition: Bipolar I Disorder
Interventions: Drug: asenapine; Drug: asenapine
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Bipolar 1 Disorder
Interventions: Drug: asenapine; Drug: placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Conditions: Cardiovascular Disease; Diabetes Mellitus, Type 2
Interventions: Drug: Dulaglutide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Crohn's Disease
Interventions: Drug: Placebo; Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Cerebral Aneurysm
Interventions: Device: HydroCoil Embolic System; Device: Control (bare platinum coils)
Sponsors: Northwestern University; Northwestern University; MicroVention, Inc
Recruiting - verified May 2013 - Condition: Schizophrenia
Intervention: Drug: OPC-34712
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified May 2013 - Condition: Acute Schizophrenia
Interventions: Drug: Dose 3; Drug: Dose 2; Drug: Dose 1; Drug: Placebo
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified May 2013 - Condition: Acute Schizophrenia
Interventions: Drug: OPC-34712; Drug: OPC-34712; Drug: OPC-34712; Drug: Placebo
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified May 2013 - Condition: Crohn's Disease
Interventions: Drug: Placebo; Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Sarcoma, Alveolar Soft Part
Interventions: Drug: Cediranib; Drug: Sunitinib
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2013 - Condition: Glioblastoma Multiforme
Interventions: Drug: PPX (CT2103); Drug: Temozolomide
Sponsors: Brown University; Brown University; Rhode Island Hospital; Milton S. Hershey Medical Center; University of Washington; University of Massachusetts, Worcester; Maine Medical Center; University of California, San Diego
Recruiting - verified May 2013 - Condition: Pulmonary Arterial Hypertension
Intervention:
Sponsors: Actelion; Actelion; Canadian Heart Research Centre
Recruiting - verified May 2013 - Condition: Epilepsy, Partial Seizures
Interventions: Drug: Pregabalin add-on therapy; Drug: Pregabalin add-on therapy; Drug: Pregabalin add-on therapy
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Condition: Diffuse Large B-Cell Lymphoma
Intervention: Drug: AEB071
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Conditions: Adenocarcinoma of the Lung; Adenosquamous Cell Lung Cancer; Bronchoalveolar Cell Lung Cancer; Large Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer
Interventions: Drug: veliparib; Other: hydrocortisone/placebo; Drug: carboplatin; Drug: paclitaxel; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Cachexia; Non-Small Cell Lung Cancer
Interventions: Drug: Anamorelin HCl; Drug: Placebo
Sponsors: Helsinn Therapeutics (U.S.), Inc; Helsinn Therapeutics (U.S.), Inc
Recruiting - verified May 2013 - Conditions: Cachexia; Non-Small Cell Lung Cancer
Interventions: Drug: Anamorelin HCl; Drug: Placebo
Sponsors: Helsinn Therapeutics (U.S.), Inc; Helsinn Therapeutics (U.S.), Inc
Recruiting - verified April 2013 - Conditions: Cachexia; Non-Small Cell Lung Cancer
Interventions: Drug: Anamorelin HCl; Drug: Placebo
Sponsors: Helsinn Therapeutics (U.S.), Inc; Helsinn Therapeutics (U.S.), Inc
Recruiting - verified May 2013 - Conditions: Congenital Bleeding Disorder; Haemophilia B
Intervention: Drug: NNC-0156-0000-0009
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013 - Conditions: Metastatic ER+ Her2- Breast Cancer; Postmenopausal
Interventions: Drug: Exemestane; Drug: Abiraterone acetate + Prednisone/ Prednisolone + Exemestane; Drug: Abiraterone acetate + Prednisone or Prednisolone
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2013 - Conditions: Brain and Central Nervous System Tumors; Cognitive/Functional Effects; Fatigue; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment
Interventions: Drug: modafinil; Other: placebo
Sponsors: University of South Florida; University of South Florida; National Cancer Institute (NCI)
Recruiting - verified September 2011 - Conditions: Age-associated Cognitive Impairment; Mild Cognitive Impairment (MCI)
Interventions: Drug: Curcumin; Dietary Supplement: Sugar pill
Sponsors: University of California, Los Angeles; University of California, Los Angeles
Recruiting - verified May 2013 - Conditions: Femoral Neck Fractures; Intertrochanteric Fracture
Interventions: Procedure: Gamma3 Intramedullary Nails (Stryker); Procedure: Sliding Hip Screws
Sponsors: Stryker Trauma GmbH; Stryker Trauma GmbH; Stryker Osteosynthesis; Global Research Solutions
Recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Interventions: Drug: PF-04171327; Drug: PF-04171327; Drug: PF-04171327; Drug: PF-04171327; Drug: prednisone; Other: prednisone; Other: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Condition: Major Depressive Disorder
Interventions: Drug: desvenlafaxine succinate sustained release; Drug: fluoxetine; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Condition: Major Depressive Disorder
Interventions: Drug: Desvenlafaxine Succinate Sustained-Release; Drug: Desvenlafaxine Succinate Sustained-Release; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Conditions: Lysosomal Acid Lipase Deficiency; Wolman Disease
Intervention: Drug: Sebelipase alfa (SBC-102)
Sponsors: Synageva BioPharma Corp.; Synageva BioPharma Corp.
Recruiting - verified January 2013 - Condition: Major Depressive Disorder
Interventions: Device: NEST-1 (NeoSync EEG Synchronized TMS); Device: SHAM
Sponsors: NeoSync, Inc.; NeoSync, Inc.
Recruiting - verified April 2013 - Condition: Liver Disease
Intervention: Drug: conivaptan hydrochloride
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified May 2013 - Conditions: Crohn's Disease; IBD; Colitis; Inflammatory Bowel Disease
Interventions: Drug: Group 2 ustekinumab 130 mg; Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified May 2013 - Conditions: Crohn's Disease; Inflammatory Bowel Disease; IBD; Colitis
Interventions: Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo; Drug: Group 2 ustekinumab 130 mg
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified May 2013 - Condition: Muscular Atrophy
Interventions: Drug: LY2495655; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Conditions: Acute Ischemic Stroke; Diabetes; Hyperglycemia
Interventions: Drug: IV insulin to maintain target glucose concentration of 80-130 mg/dL; Drug: Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL
Sponsors: University of Virginia; University of Virginia; Neurological Emergencies Treatment Trials Network (NETT); Medical University of South Carolina; Medical Automation Systems, an Alere Company; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2013 - Condition: Hepatitis B
Intervention: Drug: Entecavir and peginterferon
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of Pittsburgh
Recruiting - verified April 2013 - Condition: Hepatitis B
Interventions: Drug: Tenofovir; Drug: Combination of peginterferon alfa 2a and tenofovir
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of Pittsburgh
Recruiting - verified April 2013 - Condition: Myelofibrosis
Interventions: Drug: GS-6624 at 700 mg; Drug: GS-6624 at 200 mg
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2013 - Condition: Idiopathic Pulmonary Fibrosis (IPF)
Interventions: Drug: STX-100; Drug: Placebo
Sponsors: Stromedix, Inc.; Stromedix, Inc.
Recruiting - verified May 2013 - Conditions: Extensive Stage Small Cell Lung Cancer; Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor; Recurrent Breast Cancer; Recurrent Melanoma; Recurrent Non-small Cell Lung Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Small Cell Lung Cancer; Stage IV Borderline Ovarian Surface Epithelial-stromal Tumor; Stage IV Breast Cancer; Stage IV Melanoma; Stage IV Non-small Cell Lung Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: veliparib; Drug: paclitaxel; Drug: carboplatin; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Dystonia; Voice Disorders
Intervention:
Sponsors: Emory University; Hyder A. Jinnah, MD, PhD; National Institute of Neurological Disorders and Stroke (NINDS); Office of Rare Diseases (ORD); Allergan; Dystonia Study Group
Recruiting - verified May 2013 - Conditions: Transfusional Iron Overload; Beta-Thalassemia
Intervention: Drug: SPD602 (FBS0701, SSP-004184)
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013 - Condition: Brain Injuries
Intervention: Drug: NNZ-2566
Sponsors: Neuren Pharmaceuticals Limited; Neuren Pharmaceuticals Limited
Recruiting - verified May 2013 - Condition: Endometrial Cancer
Interventions: Drug: Carboplatin/Paclitaxel; Drug: Trastuzumab
Sponsors: Yale University; Yale University; Genentech
Recruiting - verified May 2013 - Conditions: Pain; Advanced Cancer
Interventions: Drug: Sativex®; Drug: Placebo (GA-0034)
Sponsors: GW Pharmaceuticals Ltd.; GW Pharmaceuticals Ltd.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified August 2011 - Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: placebo; Drug: trastuzumab [Herceptin]; Drug: Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Breast International Group; Genentech
Recruiting - verified May 2013 - Condition: Renal Cell Carcinoma
Interventions: Drug: BMS-936558 (Anti-PD-1); Drug: BMS-936558 (Anti-PD-1); Drug: BMS-936558 (Anti-PD-1)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharma USA Inc
Recruiting - verified May 2013 - Conditions: Acute Myeloid Leukemia; Acute Myelogenous Leukemia
Interventions: Drug: Azacitidine-single agent; Drug: Lenalidomide - single agent; Drug: Lenalidomide in combination with azacitidine
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2013 - Condition: Tumor, Solid
Intervention: Drug: MK-8353
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Fragile X Syndrome
Interventions: Drug: AFQ056; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Meningitis, Meningococcal
Interventions: Biological: rLP2086 vaccine; Biological: control
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: Hematological Malignancies; Certain Lysosomal Storage and Peroxisomal Enzyme Deficiency Disorders; Hurler Syndrome (MPS I); Krabbe Disease (Globoid Leukodystrophy); X-linked Adrenoleukodystrophy; Primary Immunodeficiency Diseases; Bone Marrow Failure; Beta-thalassemia
Intervention: Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified April 2013 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Standard of care treatment
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Normal and Diseased Tissue and Body Fluids Samples
Intervention:
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified May 2013 - Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: accelerated radiation therapy; Radiation: hypofractionated radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: whole breast irradiation
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2013 - Condition: Colorectal Neoplasms
Interventions: Drug: Eflornithine placebo & sulindac placebo; Drug: eflornithine & sulindac placebo; Drug: Eflornithine placebo & sulindac; Drug: Eflornithine plus sulindac
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI); Cancer Prevention Pharmaceuticals, Inc.
Recruiting - verified May 2013 - Condition: Urothelial Carcinoma
Interventions: Biological: DN24-02; Other: Standard of Care
Sponsors: Dendreon; Dendreon
Recruiting - verified April 2013 - Conditions: Primary Myelofibrosis; Post Essential Thrombocythemia-myelofibrosis; Post Polycythemia Vera-myelofibrosis
Intervention: Drug: Ruxolitinib (INCB018424)
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified May 2013 - Condition: Advanced Cancer
Interventions: Drug: PF-05212384; Drug: PD-0325901; Drug: PF-05212384; Drug: irinotecan
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: Brain and Central Nervous System Tumors; Nausea and Vomiting; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Procedure: Real Acupressure Band; Procedure: Placebo Acupressure Band
Sponsors: University of South Florida; University of South Florida; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Neoplasms
Intervention: Biological: IMC-CS4
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified November 2012 - Conditions: Cancer; Hematologic Malignancies; Multiple Myeloma; Oncology; Bone Metastases; Multiple Myeloma Bone Lesions
Interventions: Drug: Denosumab; Drug: Zoledronic acid
Sponsors: Amgen; Amgen; Daiichi Sankyo Inc.
Recruiting - verified May 2013 - Condition: Head and Neck Neoplasms
Interventions: Drug: Placebo; Drug: Afatinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Crohn's Disease
Interventions: Biological: PF-04236921; Biological: PF-04236921
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: HIV-1
Interventions: Drug: Maraviroc; Drug: Emtricitabine/tenofovir
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2013 - Condition: Atrophy, Geographic
Interventions: Drug: GSK933776; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2013 - Condition: Advanced Liposarcoma or Leiomyosarcoma
Interventions: Drug: Trabectedin; Drug: Dacarbazine
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharma Mar, S.A.U.
Recruiting - verified May 2013 - Condition: Hypertension, Pulmonary
Intervention: Drug: Ambrisentan
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Microvascular Coronary Dysfunction (MCD)
Interventions: Drug: Ranolazine; Drug: Placebo
Sponsors: Cedars-Sinai Medical Center; Cedars-Sinai Medical Center; University of Florida
Recruiting - verified May 2013 - Conditions: Infant, Newborn; Infant, Small for Gestational Age; Infant, Very Low Birth Weight; Infant, Premature; Bronchopulmonary Dysplasia
Interventions: Drug: Hydrocortisone; Drug: Placebo
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR)
Recruiting - verified May 2013 - Conditions: Bone Cancer; Chondrosarcoma; Ewing's Sarcoma; Osteosarcoma; Rhabdomyosarcoma
Interventions: Drug: Feraheme; Procedure: MR Scan
Sponsors: Stanford University; Stanford University
Recruiting - verified May 2013 - Condition: Cardiovascular Disease, Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: etanercept
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Cancer
Intervention: Drug: GSK2118436
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013 - Condition: Hepatitis C
Interventions: Drug: BI 201335; Drug: PegIFN/RBV
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: Placebo; Drug: erlotinib [Tarceva]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Fluticasone Furoate/Vilanterol; Drug: Vilanterol; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013 - Condition: Breast Neoplasms
Interventions: Drug: Afatinib once daily (OD); Drug: Vinorelbine Weekly
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Hepatitis C
Intervention: Drug: TMC435
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified May 2013 - A Phase 3 Efficacy Study of a Recombinant Vaccinia Virus Vaccine to Treat Metastatic Prostate CancerCondition: Prostate Cancer Metastatic
Interventions: Biological: PROSTVAC-V; Biological: PROSTVAC-F; Drug: GM-CSF; Other: GM-CSF Placebo; Biological: Placebo
Sponsors: BN ImmunoTherapeutics; BN ImmunoTherapeutics
Recruiting - verified February 2013 - Condition: Glaucoma
Intervention:
Sponsors: Oregon Health and Science University; Oregon Health and Science University; National Eye Institute (NEI)
Recruiting - verified May 2013 - Condition: Neuroblastoma
Intervention: Drug: Metaiodobenzylguanidine (MIBG)
Sponsors: University of California, San Francisco; University of California, San Francisco; Thrasher Research Fund
Recruiting - verified May 2013 - Condition: Smoking Cessation
Interventions: Drug: Varenicline 1mg BID; Drug: Varenicline 0.5mg BID; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Symptomatic Severe Aortic Stenosis
Interventions: Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: AVR with a surgical heart valve; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: AVR with a surgical heart valve; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis
Sponsors: Edwards Lifesciences; Edwards Lifesciences
Recruiting - verified April 2013 - Conditions: Breast Cancer; Early Stage
Intervention: Radiation: Proton Beam Radiotherapy
Sponsors: Loma Linda University; Loma Linda University
Recruiting - verified May 2013 - Conditions: Prostate Cancer; Prostatic Neoplasm
Intervention: Drug: abiraterone acetate in combination with prednisone
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified April 2013 - Condition: Crohn's Disease
Intervention: Drug: GSK1605786A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Crohn's Disease
Interventions: Drug: GSK1605786A; Drug: Placebo; Drug: GSK1605786A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Influenza, Human
Interventions: Drug: Oseltamivir; Drug: Oseltamivir Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013 - Conditions: HIV Infection; Cardiovascular Disease; Inflammation
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Bronchiolitis Obliterans
Interventions: Drug: fluticasone propionate; Drug: montelukast sodium; Procedure: pulmonary function testing; Other: questionnaire administration; Procedure: quality-of-life assessment; Other: laboratory biomarker analysis; Genetic: protein analysis; Drug: azithromycin
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Advanced Prostate Cancer; Prostatic Neoplasms
Intervention: Biological: sipuleucel-T
Sponsors: Dendreon; Dendreon
Recruiting - verified May 2013 - Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: PF-05082566; Drug: rituximab; Drug: PF-05082566
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Warfarin Therapy
Intervention: Device: Warfarin GenoSTAT Test
Sponsors: Iverson Genetic Diagnostics, Inc.; Iverson Genetic Diagnostics, Inc.
Recruiting - verified April 2013 - Condition: Depression
Interventions: Drug: Armodafinil; Drug: Placebo
Sponsors: Teva Pharmaceutical Industries; Cephalon
Recruiting - verified April 2013 - Conditions: Left Ventricular Dysfunction; Heart Failure
Interventions: Device: CardioFit® System; Other: Standard of Care
Sponsors: BioControl Medical; BioControl Medical
Recruiting - verified May 2013 - Conditions: Metastatic Cancer; Cancer; Solid Tumors
Intervention: Drug: BIND-014
Sponsors: BIND Therapeutics; BIND Therapeutics
Recruiting - verified April 2013 - Conditions: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Chronic Myeloid Leukemia; Myelodysplasia
Interventions: Biological: human myeloid progenitor cells; Drug: G-CSF
Sponsors: Cellerant Therapeutics; Cellerant Therapeutics; Department of Health and Human Services
Recruiting - verified May 2013 - Condition: Cancer, Solid Tumor
Interventions: Drug: lambrolizumab 1 mg/kg; Drug: lambrolizumab 3 mg/kg; Drug: lambrolizumab 10 mg/kg; Drug: lambrolizumab MEL; Drug: lambrolizumab NSCLC; Drug: lambrolizumab MEL Low Dose; Drug: lambrolizumab MEL High Dose; Drug: lambrolizumab NSCLC Low Dose; Drug: lambrolizumab NSCLC High Dose; Drug: lambrolizumab NSCLC Medium Dose
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Colorectal Cancer
Interventions: Biological: Imprime PGG + cetuximab; Drug: Cetuximab
Sponsors: Biothera; Biothera
Recruiting - verified May 2013 - Condition: Lymphoma, B-Cell
Interventions: Drug: RO5072759; Drug: rituximab [MabThera/Rituxan]; Drug: CHOP chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Fondazione Italiana Linfomi ONLUS
Recruiting - verified May 2013 - Condition: Prostate Cancer
Intervention: Radiation: Radiation Therapy
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center; Fox Chase Cancer Center; Cedars-Sinai Medical Center; Washington University School of Medicine
Recruiting - verified May 2013 - Condition: Anemia
Interventions: Drug: LY2787106; Dietary Supplement: Iron Supplementation
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Chronic Ischemic Stroke
Intervention: Biological: SB623
Sponsors: SanBio, Inc.; SanBio, Inc.
Recruiting - verified May 2013 - Condition: Crohn's Disease
Intervention: Drug: PF-00547659
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Tumors Characterized by Genetic Abnormalities of ALK
Intervention: Drug: LDK378
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Lung Cancer - Non Small Cell
Interventions: Drug: Ipilimumab; Drug: Placebo; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013 - Conditions: Carcinoma of Urinary Tract; Urethral Carcinoma; Carcinoma of Ureter; Carcinoma of Renal Pelvis
Interventions: Drug: Docetaxel; Biological: Ramucirumab DP; Biological: IMC-18F1
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified February 2013 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cancer
Interventions: Drug: AMG386 plus PLD; Drug: Placebo plus PLD
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Condition: Asthma
Interventions: Drug: tiotropium high dose; Drug: placebo; Drug: tiotropium low dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting - verified May 2013 - Condition: Crohn's Disease
Interventions: Drug: PF-00547659 SC injection; Drug: PF-00547659 SC injection; Drug: PF-00547659 SC injection; Drug: PF-00547659 SC injection
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast CancerConditions: Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: docetaxel; Drug: cyclophosphamide; Biological: trastuzumab; Drug: paclitaxel; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Glioblastoma Multiforme
Interventions: Drug: Amgen 386; Drug: Bevacizumab
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Amgen
Recruiting - verified May 2013 - Conditions: Recurrent Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma
Interventions: Biological: ipilimumab; Biological: recombinant interferon alfa-2b; Other: pharmacological study; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified April 2013 - Conditions: Neoplasms; Lymphomas
Intervention: Drug: Belinostat
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2012 - Condition: Malignant Melanoma
Interventions: Drug: vemurafenib; Drug: GDC-0973
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Post Herpetic Neuralgia
Interventions: Drug: Pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Smoking
Interventions: Behavioral: Integrated Care; Behavioral: Cognitive-Behavioral Treatment for Insomnia; Behavioral: Desensitization Treatment for Insomnia
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2013 - Conditions: Idiopathic Bronchiectasis; Nontuberculous Mycobacterium (NTM) Infection
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified September 2012 - Conditions: Dysphagia; Lung Cancer; Pain
Interventions: Drug: Manuka honey; Drug: chemotherapy; Other: questionnaire administration; Procedure: adjuvant therapy; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment; Procedure: standard follow-up care; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2013 - Condition: Hypertension
Interventions: Behavioral: Mindful Breathing (MB) Intervention; Behavioral: Usual Care (UC) Control Condition
Sponsors: University of California, San Francisco; University of California, San Francisco; National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified May 2013 - Condition: Epilepsy
Interventions: Drug: Placebo; Drug: Brivaracetam; Drug: Brivaracetam
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified April 2013 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Welchol for oral suspension placebo proxy; Drug: Welchol for oral suspension
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified May 2013 - Condition: Herpes Zoster
Interventions: Biological: V212; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: HIV Infection
Interventions: Behavioral: Bruthas Project; Behavioral: Standard HIV Testing and Counseling
Sponsors: University of California, San Francisco; University of California, San Francisco; National Institute of Mental Health (NIMH)
Recruiting - verified May 2013 - Conditions: Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer
Interventions: Drug: Akt inhibitor MK2206; Drug: bicalutamide; Other: clinical observation
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Neuroendocrine Tumors; Carcinoid Tumors
Intervention: Drug: Pasireotide Long Acting Release (LAR)
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: ocrelizumab; Drug: Rebif; Drug: ocrelizumab placebo; Drug: Rebif placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Bipolar Disorder, Pediatric
Interventions: Drug: asenapine; Drug: Placebo to match asenapine; Drug: Rescue medication
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Critical Limb Ischemia
Interventions: Device: BMAC injection; Device: Placebo injection
Sponsors: Harvest Technologies; Harvest Technologies
Recruiting - verified April 2013 - Condition: Colitis, Ulcerative
Interventions: Drug: placebo; Drug: MultiStem low dose; Drug: placebo; Drug: MultiStem low dose; Drug: placebo; Drug: MultiStem high dose; Drug: placebo; Drug: MultiStem high dose; Drug: placebo; Drug: MultiStem high dose; Drug: placebo; Drug: MultiStem high dose
Sponsors: Pfizer; Pfizer; Athersys, Inc
Recruiting - verified May 2013 - Condition: Colorectal Cancer
Interventions: Procedure: Colonoscopy; Procedure: FIT
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2013 - Condition: Prostate Cancer
Interventions: Behavioral: telephone-based intervention; Other: counseling intervention; Other: educational intervention; Procedure: therapeutic dietary intervention
Sponsors: Alliance for Clinical Oncology Trials; Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified April 2013 - Condition: Small Cell Lung Cancer
Interventions: Drug: IMGN901; Drug: Carboplatin and Etoposide
Sponsors: ImmunoGen, Inc.; ImmunoGen, Inc.
Recruiting - verified April 2013 - Conditions: Childhood High-grade Cerebellar Astrocytoma; Childhood High-grade Cerebral Astrocytoma; Childhood Spinal Cord Neoplasm; Untreated Childhood Brain Stem Glioma; Untreated Childhood Cerebral Astrocytoma
Interventions: Drug: vorinostat; Biological: bevacizumab; Drug: temozolomide
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Hypertension, Pulmonary
Interventions: Drug: inhaled treprostinil; Drug: tadalafil
Sponsors: Stanford University; Stanford University; Northwestern University
Recruiting - verified May 2013 - Condition: Crohn's Disease
Intervention: Drug: adult human mesenchymal stem cells
Sponsors: Osiris Therapeutics; Osiris Therapeutics
Recruiting - verified January 2013 - Condition: Influenza, Human
Interventions: Drug: 300mg intravenous (IV) zanamivir and oral oseltamivir placebo; Drug: 600mg intravenous (IV) zanamivir and oral oseltamivir placebo; Drug: 75mg oral oseltamivir and intravenous zanamivir placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Conditions: Mild Cognitive Impairment (MCI); Alzheimer's Disease
Intervention:
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); Alzheimer's Disease Cooperative Study (ADCS); Northern California Institute for Research and Education (NCIRE); National Institute on Aging (NIA)
Recruiting - verified May 2013 - Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Inotuzumab ozogamicin; Drug: Rituximab; Drug: rituximab + gemcitabine; Drug: rituximab +bendamustine
Sponsors: Pfizer; Pfizer; UCB, Inc.
Recruiting - verified May 2013 - Condition: Non Small Cell Lung Carcinoma
Interventions: Drug: AZD6244; Drug: Erlotinib; Drug: AZD6244 + Erlotinib
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2013 - Condition: Influenza
Interventions: Drug: Amantadine, Ribavirin, Oseltamivir; Drug: Oseltamivir
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013 - Condition: Cancer
Interventions: Drug: GSK2118436; Drug: GSK1120212; Drug: Other approved anti-cancer agent
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Age-related Macular Degeneration
Intervention: Biological: CNTO 2476
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013 - Conditions: Acute Myocardial Infarction; Congestive Heart Failure; ST-Elevation Myocardial Infarction
Interventions: Device: Sodium Alginate and Calcium Gluconate; Device: Saline Solution
Sponsors: Ikaria Holdings Inc.; Ikaria Holdings Inc.
Recruiting - verified May 2013 - Condition: Stroke
Intervention:
Sponsors: National Stroke Association, United States; National Stroke Association, United States; University of Southern California; Mayo Clinic; Swedish Medical Center; University of Utah; California Pacific Medical Center
Recruiting - verified May 2013 - Condition: Portopulmonary Hypertension
Intervention: Drug: Ambrisentan
Sponsors: Tufts Medical Center; Tufts Medical Center; Gilead Sciences
Recruiting - verified May 2013 - Condition: Cancer
Interventions: Drug: pazopanib; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Alzheimer Disease
Interventions: Drug: gantenerumab; Drug: gantenerumab; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Glioma
Interventions: Drug: LY2157299; Drug: Radiation; Drug: Temozolomide
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Stroke
Interventions: Drug: GM602; Drug: Matching Placebo (Bacteriostatic Saline) for GM602
Sponsors: Genervon Biopharmaceuticals, LLC; Genervon Biopharmaceuticals, LLC; University of California, Los Angeles; Huntington Hospital; Hoag Memorial Hospital Presbyterian; Columbia University; California Pacific Medical Center Research Institute; Erlanger Healthcare System; Sarasota Memorial Hospital; University of Louisville
Recruiting - verified May 2013 - Conditions: Prostate Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male
Intervention: Drug: Abiraterone Acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2013 - Condition: Breast Cancer
Interventions: Drug: Sorafenib(Nexavar, BAY43-9006) / Capecitabine; Drug: Placebo / Capecitabine
Sponsors: Bayer; Bayer; Onyx Therapeutics, Inc.
Recruiting - verified May 2013 - Conditions: Acute Myocardial Infarction; Pacing Therapy; Cardiac Remodeling; Heart Failure
Interventions: Device: Single Site Pacing; Device: Dual Site Pacing
Sponsors: Medtronic Cardiac Rhythm Disease Management; Medtronic Cardiac Rhythm Disease Management
Recruiting - verified May 2013 - Conditions: Anal Cancer; Nonneoplastic Condition; Penile Cancer; Precancerous Condition
Interventions: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; Other: laboratory biomarker analysis
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Disseminated Neuroblastoma; Localized Unresectable Neuroblastoma; Recurrent Neuroblastoma; Regional Neuroblastoma; Stage 4S Neuroblastoma
Interventions: Drug: vorinostat; Drug: isotretinoin; Other: diagnostic laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Hepatocellular Carcinoma
Interventions: Drug: Axitinib (AG-013736); Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Arthritis, Rheumatoid
Interventions: Drug: Etoricoxib 60 mg; Drug: Etoricoxib 90 mg; Drug: Placebo to Etoricoxib 60 mg; Drug: Placebo to Etoricoxib 90 mg
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Spondylitis, Ankylosing
Interventions: Drug: Part I - etoricoxib 60 mg; Drug: Part I - etoricoxib 90 mg; Drug: Part I- naproxen 1000 mg; Drug: Part I - Placebo to naproxen 500 mg; Drug: Part II- etoricoxib 60 mg; Drug: Part II- etoricoxib 90 mg; Drug: Part II- naproxen 1000 mg
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Conditions: Graft vs Host Disease; Cutaneous Sclerosis; Bronchiolitis Obliterans
Intervention:
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified April 2013 - Conditions: Systemic Lupus Erythematosus; Connective Tissue Disease; Autoimmune Disease
Interventions: Drug: LY2127399; Drug: Placebo every 2 weeks; Drug: Placebo every 4 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Lymphoma, Follicular
Interventions: Biological: Ofatumumab; Biological: Rituximab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013 - Conditions: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Myelodysplastic Syndrome; Lymphomas; Bone Marrow Failure; Hemoglobinopathy; Immune Deficiency; Osteopetrosis; Cytopenias; White Blood Cell Abnormalities; Red Blood Cell Abnormalities
Intervention: Biological: CD34+ enriched, T Cell Depleted donor stem cell product
Sponsors: University of California, San Francisco; University of California, San Francisco
Available - verified May 2013 - Conditions: Systemic Lupus Erythematosus; Connective Tissue Disease; Autoimmune Disease
Interventions: Drug: LY2127399; Drug: Placebo every 2 weeks; Drug: Placebo every 4 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Multiple Sclerosis, Primary Progressive
Interventions: Drug: ocrelizumab; Drug: Placebo; Drug: methylprednisolone
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Bacteremia
Interventions: Drug: Vancomycin; Drug: Vancomycin
Sponsors: Duke University; Duke University; National Institutes of Health (NIH)
Recruiting - verified April 2013 - Conditions: Cutaneous Lymphoma; Cutaneous T-cell Lymphoma
Interventions: Procedure: TSEBT; Drug: Vorinostat
Sponsors: Stanford University; Stanford University
Recruiting - verified April 2013 - Condition: Diffuse Intrinsic Pontine Glioma
Interventions: Drug: Bevacizumab; Drug: Erlotinib; Drug: Temozolomide; Radiation: Irradiation
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Children's Hospital Boston; University of California, San Francisco; Ann & Robert H Lurie Children's Hospital of Chicago; Children's Healthcare of Atlanta; Children's Hospital Colorado; Children's Hospital Los Angeles; Children's Hospital of Michigan; Children's Hospitals and Clinics of Minnesota; Cook Children's Medical Center; Doernbecher Children's Hospital; Duke University; Johns Hopkins University; Memorial Sloan-Kettering Cancer Center; Miami Children's Hospital; New York University; Penn State Hershey Medical Center; Seattle Children's; University of Louisville; University of Mississippi Medical Center; UT Southwestern Medical Center; Washington University Medical Center
Recruiting - verified May 2013 - Condition: Colorectal Cancer
Interventions: Biological: Ramucirumab; Drug: Irinotecan; Biological: Placebo; Drug: Folinic Acid; Drug: 5-Fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company; ImClone LLC
Recruiting - verified May 2013 - Condition: Intracerebral Hemorrhage
Intervention: Drug: Nicardipine hydrochloride
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; Medical University of South Carolina; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2013 - Conditions: Minimal Change Disease (MCD); Membranous Nephropathy; Glomerulosclerosis, Focal Segmental
Intervention:
Sponsors: University of Michigan; University of Michigan; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); The NephCure Foundation
Recruiting - verified April 2013 - Condition: Major Depressive Disorder
Interventions: Drug: LY2216684; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: HIV
Intervention: Drug: Lopinavir/ritonavir
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013 - Conditions: Light Chain Deposition Disease; Smoldering Multiple Myeloma
Interventions: Other: clinical observation; Drug: lenalidomide; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Contrast Induced Nephropathy
Interventions: Device: CINCOR™ System; Drug: Peri-procedural hydration
Sponsors: Osprey Medical, Inc; Osprey Medical, Inc
Recruiting - verified April 2013 - Condition: Cytomegalovirus Infections, Heart Transplantation
Intervention: Drug: valganciclovir [Valcyte]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Hypertension, Pulmonary
Interventions: Drug: ambrisentan; Drug: tadalafil
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Gilead Sciences
Recruiting - verified May 2013 - Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma
Interventions: Drug: bortezomib; Drug: fludarabine phosphate; Other: melphalan; Radiation: total marrow irradiation; Drug: tacrolimus; Drug: sirolimus; Procedure: peripheral blood stem cell transplantation; Other: laboratory biomarker analysis
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Biological: 1121B (ramucirumab); Drug: Pemetrexed; Drug: Carboplatin (AUC 6); Drug: Cisplatin; Drug: Gemcitabine; Drug: Carboplatin (AUC 5)
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified March 2013 - Condition: Glioma
Intervention: Drug: RAD001 (Everolimus)
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; Children's Hospital Boston; Children's Hospital of Philadelphia; Children's Research Institute; Children's Hospital Medical Center, Cincinnati; National Cancer Institute (NCI); University of Chicago; University of Utah; Washington University School of Medicine
Recruiting - verified April 2013 - Condition: Ulcerative Colitis
Intervention: Drug: Amg 181
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Condition: Neoplasms, Breast
Interventions: Drug: lapatinib; Drug: trastuzumab; Drug: Aromatase inhibitor; Drug: lapatinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Bladder Cancer Requiring Cystectomy
Interventions: Other: Quality of Life Questionnaires; Other: Get up and Go test; Other: Hand Grip test
Sponsors: University of Miami; University of Miami; National Cancer Institute (NCI)
Recruiting - verified April 2013 - Condition: Non Squamous Lung Cancer
Interventions: Drug: treatment; Drug: treatment
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Breast Cancer
Intervention: Device: Radiofrequency Ablation
Sponsors: University of Arkansas; University of Arkansas; Angiodynamics, Inc.
Recruiting - verified April 2013 - Condition: Hypertension
Interventions: Drug: Aliskiren; Drug: Aliskiren; Drug: Aliskiren
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2013 - Condition: Schizophrenia
Interventions: Drug: Aripiprazole; Drug: Aripiprazole
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified May 2013 - Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013 - Conditions: Venous Thrombosis; Pediatrics
Intervention: Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsors: Bayer; Bayer; Janssen Research & Development, LLC
Recruiting - verified May 2013 - Condition: Smallpox
Interventions: Biological: IMVAMUNE; Biological: IMVAMUNE; Biological: IMVAMUNE; Other: Placebo
Sponsors: Bavarian Nordic; Bavarian Nordic
Recruiting - verified May 2013 - Condition: Spinal Cord Injuries
Intervention: Behavioral: Vocational Rehabilitation
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2013 - Condition: Cancer
Interventions: Drug: cyproheptadine hydrochloride; Other: placebo
Sponsors: University of South Florida; University of South Florida; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Thrombocytopaenia
Interventions: Drug: Eltrombopag olamine; Other: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013 - Condition: Pneumococcal Disease
Intervention: Other: No Intervention
Sponsors: Pfizer; Pfizer; Kaiser Permanente
Recruiting - verified May 2013 - Condition: Cancer
Intervention:
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; National Cancer Institute (NCI); Fred Hutchinson Cancer Research Center; Nationwide Children's Hospital; M.D. Anderson Cancer Center; University of Southern California; Children's Hospital Medical Center, Cincinnati
Recruiting - verified April 2013 - Condition: Hepatitis C, Chronic
Interventions: Drug: BI 207127; Drug: BI 201335; Drug: BI 207127; Drug: BI 201335; Drug: Ribavirin; Drug: Ribavirin; Drug: Ribavirin; Drug: BI 207127; Drug: BI 207127; Drug: BI 207127; Drug: BI 201335; Drug: Ribavirin; Drug: Ribavirin; Drug: BI 207127; Drug: BI 207127; Drug: BI 201335; Drug: BI 201335; Drug: Ribavirin; Drug: BI 201335; Drug: BI 201335; Drug: BI 207127; Drug: BI 201335; Drug: BI 201335; Drug: BI 207127; Drug: BI 201335; Drug: Ribavirin; Drug: Ribavirin; Drug: BI 207217; Drug: BI 201335; Drug: BI 207127; Drug: Ribavirin; Drug: BI 207127; Drug: BI 201335; Drug: Ribavirin; Drug: Ribavirin
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Respiratory Distress Syndrome
Interventions: Device: Nasal continuous positive airway pressure (nCPAP); Device: Laryngeal Mask Airway (LMA) to deliver surfactant
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute
Recruiting - verified April 2013 - Conditions: Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; Ovarian Endometrioid Adenocarcinoma; Ovarian Papillary Serous Carcinoma; Ovarian Serous Cystadenocarcinoma; Progesterone Receptor-negative Breast Cancer; Recurrent Breast Cancer; Recurrent Fallopian Tube Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity Cancer; Triple-negative Breast Cancer
Interventions: Drug: olaparib; Drug: cediranib maleate; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Diabetic Kidney Disease; Diabetic Nephropathy; Diabetic Glomerulosclerosis
Interventions: Drug: LY2382770; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Stroke, Acute
Interventions: Device: hypothermia; Other: Group1: IV t-PA and normothermia
Sponsors: University of California, San Diego; University of California, San Diego; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2013 - Condition: Peripheral T-cell Lymphoma
Intervention:
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc
Recruiting - verified May 2013 - Condition: Complicated Urinary Tract Infections or Pyelonephritis
Interventions: Drug: doripenem; Drug: doripenem placebo; Drug: cefepime; Drug: cefepime placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2013 - Conditions: Traumatic Brain Injury; Post-traumatic Stress Disorder
Intervention:
Sponsors: International Hyperbaric Medical Foundation; International Hyperbaric Medical Foundation
Recruiting - verified April 2013 - Conditions: Abscess, Intra-Abdominal; Abdominal Abscess; Abdomen, Acute; Abdominal Pain; Appendicitis; Rupture; Infection; Intestinal Perforation; Peritonitis; Ileus
Interventions: Drug: doripenem; Drug: meropenem placebo; Drug: meropenem; Drug: doripenem placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013 - Condition: Includes: Hereditary Angioedema
Intervention: Biological: Berinert® (C1 Esterase Inhibitor)
Sponsors: CSL Behring; CSL Behring; Chiltern International Inc.
Recruiting - verified May 2013 - Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Selexipag (ACT-293987); Drug: Placebo
Sponsors: Actelion; Actelion
Recruiting - verified May 2013 - Conditions: Fibromyalgia; Irritable Bowel Syndrome; Fatigue Syndrome, Chronic
Intervention:
Sponsors: University of Pennsylvania; University of Pennsylvania; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of Colorado, Denver
Recruiting - verified May 2013 - Conditions: Interstitial Cystitis; Chronic Prostatitis
Intervention:
Sponsors: University of Pennsylvania; University of Pennsylvania; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of Colorado, Denver
Recruiting - verified May 2013 - Conditions: brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer
Interventions: Dietary Supplement: cholecalciferol; Other: placebo
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Relapsed/Refractory Multiple Myeloma
Interventions: Drug: plitidepsin + dexamethasone; Drug: dexamethasone
Sponsors: PharmaMar; PharmaMar
Recruiting - verified March 2013 - Condition: Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
Interventions: Biological: Rituximab; Other: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013 - Condition: Hematological Malignancy
Intervention: Drug: SAR650984
Sponsors: Sanofi; Sanofi
Recruiting - verified April 2013 - Conditions: Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia
Intervention: Drug: Nilotinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Pancreatic Cancer
Interventions: Biological: HyperAcute-Pancreas Immunotherapy; Drug: Gemcitabine; Radiation: 5FU Chemoradiation
Sponsors: NewLink Genetics Corporation; NewLink Genetics Corporation
Recruiting - verified May 2013 - Condition: Intraabdominal Infections
Interventions: Drug: Moxifloxacin (Avelox, BAY12-8039); Drug: Ertapenem, Amoxicillin/clavulanate
Sponsors: Bayer; Bayer
Recruiting - verified April 2013 - Conditions: Advanced Malignant Mesothelioma; Epithelial Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatous Mesothelioma
Interventions: Drug: pemetrexed disodium; Drug: cisplatin; Drug: cediranib maleate; Other: placebo
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Clear Cell Sarcoma of the Kidney; Recurrent Renal Cell Cancer; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer
Interventions: Drug: dalteparin; Drug: sunitinib malate; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: dynamic contrast-enhanced magnetic resonance imaging; Other: immunohistochemistry staining method
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified April 2013 - Condition: Pain
Intervention: Procedure: Real-time fMRI feedback
Sponsors: Stanford University; Stanford University
Not yet recruiting - verified May 2013 - Condition: Non-infectious, Non-necrotizing Anterior Scleritis
Interventions: Drug: Dexamethasone Phosphate Ophthalmic Solution (EGP-437); Drug: Dexamethasone phosphate ophthalmic solution
Sponsors: University of Pennsylvania; John Kempen
Recruiting - verified April 2013 - Condition: Influenza
Intervention:
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health (NIH)
Recruiting - verified May 2013 - Condition: Chronic Pain
Interventions: Behavioral: In-Person Acceptance and Commitment Therapy; Behavioral: Telehealth Acceptance and Commitment Therapy
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2013 - Condition: Influenza A
Interventions: Biological: Anti-Influenza Plasma; Behavioral: Standard Care
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013 - Condition: Infections
Intervention: Drug: Moxifloxacin (Avelox, BAY12-8039)
Sponsors: Bayer; Bayer
Recruiting - verified May 2013 - Condition: Leukaemia, Lymphocytic, Chronic
Interventions: Biological: Ofatumumab; Other: Observation
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Intervention: Biological: Romiplostim
Sponsors: Amgen; Amgen
Recruiting - verified April 2013 - Condition: Heart Failure With Reduced Ejection Fraction
Interventions: Drug: LCZ696 200 mg BID; Drug: Enalapril 10 mg BID
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2013 - Condition: Renal Cell Carcinoma
Interventions: Drug: Everolimus; Drug: BNC105P; Drug: Everolimus; Drug: BNC105P
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Bionomics Limited
Recruiting - verified May 2013 - Condition: Cytomegalovirus Infections
Intervention:
Sponsors: QIAGEN Gaithersburg, Inc; QIAGEN Gaithersburg, Inc
Recruiting - verified April 2013 - Condition: Neuroblastoma
Interventions: Drug: Vorinostat; Radiation: 131- I Metaiodobenzylguanidine; Procedure: Peripheral Blood Stem Cell Infusion; Drug: Filgrastim
Sponsors: New Approaches to Neuroblastoma Therapy Consortium; New Approaches to Neuroblastoma Therapy Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2013 - Condition: Fibromyalgia
Interventions: Drug: placebo; Drug: pregabalin (Lyrica)
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Condition: Fibromyalgia
Intervention: Drug: pregabalin
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Condition: Autism
Interventions: Behavioral: Discrete Trial Training; Behavioral: Interpersonal Developmental Approach
Sponsors: University of California, Los Angeles; University of California, Los Angeles; National Institute of Mental Health (NIMH)
Recruiting - verified May 2013 - Condition: Healthy
Interventions: Drug: GLYX-13; Drug: IV normal saline
Sponsors: Naurex, Inc; Naurex, Inc
Recruiting - verified September 2012 - Conditions: Breast Cancer; Cardiac Toxicity
Interventions: Drug: Coreg CR®; Drug: lisinopril; Other: placebo
Sponsors: University of South Florida; University of South Florida; National Cancer Institute (NCI)
Recruiting - verified January 2013 - Condition: Lymphocytic Leukemia, Chronic
Interventions: Drug: RO5072759; Drug: rituximab; Drug: chlorambucil
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Genentech; German CLL Study Group
Recruiting - verified May 2013 - Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Trastuzumab; Drug: Neratinib; Drug: Doxorubicin; Drug: Cyclophosphamide
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); Puma Biotechnology, Inc.
Recruiting - verified April 2013 - Condition: Lung Cancer
Interventions: Drug: PF-00299804; Drug: Placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified April 2013 - Conditions: Central Nervous System Metastases; Leptomeningeal Metastases; Recurrent Breast Cancer; Stage IV Breast Cancer; Tumors Metastatic to Brain
Interventions: Drug: methotrexate; Drug: liposomal cytarabine; Other: quality-of-life assessment; Other: questionnaire administration
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Ischemic Attack, Transient
Interventions: Drug: Clopidogrel; Drug: placebo
Sponsors: University of California, San Francisco; University of California, San Francisco; Neurological Emergencies Treatment Trials Network (NETT); Medical University of South Carolina; The EMMES Corporation
Recruiting - verified May 2013 - Conditions: Influenza A Virus Infection; Swine Flu
Intervention: Biological: Plasma collection following infection or vaccination with influenza A
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013 - Conditions: HIV Infections; HIV-1
Intervention: Drug: Etravirine
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified May 2013 - Condition: C. Trachomatis
Interventions: Drug: Doxycycline; Drug: Azithromycin
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013 - Condition: Sepsis Induced ALI
Interventions: Drug: Rosuvastatin; Drug: Placebo
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2013 - Conditions: Head and Neck Neoplasms; Lung Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms
Interventions: Drug: 5-Fluoro-2-Deoxycytidine (FdCyd); Drug: Tetrahydrouridine (THU)
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified December 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Nasal Type Extranodal NK/T-cell Lymphoma; AIDS-related Diffuse Large Cell Lymphoma; AIDS-related Diffuse Mixed Cell Lymphoma; AIDS-related Diffuse Small Cleaved Cell Lymphoma; AIDS-related Immunoblastic Large Cell Lymphoma; AIDS-related Lymphoblastic Lymphoma; AIDS-related Peripheral/Systemic Lymphoma; AIDS-related Small Noncleaved Cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Blastic Phase Chronic Myelogenous Leukemia; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Burkitt Lymphoma; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; HIV-associated Hodgkin Lymphoma; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Secondary Myelodysplastic Syndromes
Interventions: Procedure: leukapheresis; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Other: laboratory biomarker analysis; Other: DNA analysis; Other: RNA analysis; Other: flow cytometry; Other: reverse transcriptase-polymerase chain reaction; Other: nucleic acid sequencing; Other: protein expression analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2013 - Condition: Cancer
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Idiopathic Venous Thromboembolism
Intervention: Other: Application of the"Men continue and HER DOO2" rule
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; Biomerieux
Recruiting - verified April 2013 - Condition: Alzheimer Disease
Intervention: Drug: ACC-001+ QS21
Sponsors: Pfizer; Pfizer; JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Recruiting - verified May 2013 - Conditions: Distal Urethral Cancer; Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter; Proximal Urethral Cancer; Recurrent Bladder Cancer; Recurrent Prostate Cancer; Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter; Recurrent Urethral Cancer; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Transitional Cell Carcinoma of the Bladder; Urethral Cancer Associated With Invasive Bladder Cancer
Interventions: Drug: gemcitabine hydrochloride; Drug: cisplatin; Other: placebo; Biological: bevacizumab; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Epilepsy
Intervention: Drug: Lacosamide
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified April 2013 - Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: PF-02341066
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: Pain, Burning; Pain, Crushing; Pain, Migratory; Pain, Radiating; Pain, Splitting
Interventions: Drug: JNJ-42160443; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2013 - Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Condition: Glioblastoma Multiforme
Interventions: Device: NovoTTF-100A device; Drug: Temozolomide
Sponsors: NovoCure Ltd.; NovoCure Ltd.
Recruiting - verified May 2013 - Conditions: Need for MRI Imaging With Pacemaker or; Implantable Cardioverter Defibrillator Implanted
Intervention: Device: MRI with pacemaker or ICD
Sponsors: Scripps Health; Scripps Health; The Scripps Foundation; The Hewitt Medical Research Foundation; St. Jude Medical; Boston Scientific Corporation; Biotronik, Inc.
Recruiting - verified August 2012 - Condition: Inflammatory Bowel Disease
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco; Crohn's and Colitis Foundation
Recruiting - verified May 2013 - Conditions: Atypical Endocervical Glandular Cell of Undetermined Significance; Atypical Endometrial Hyperplasia; Atypical Glandular Cell of Undetermined Significance; Cervical Cancer; Cervical Intraepithelial Neoplasia Grade 2; Cervical Intraepithelial Neoplasia Grade 3; Human Papilloma Virus Infection
Intervention: Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified April 2013 - Conditions: Graft Rejection; Kidney Transplant; Renal Allograft Recipients; Renal Transplant
Interventions: Drug: Tacrolimus; Drug: Sirolimus; Drug: Tacrolimus
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Condition: Osteoporosis
Interventions: Drug: Teriparatide; Drug: Risedronate; Drug: Placebo; Dietary Supplement: Calcium; Dietary Supplement: Vitamin D
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Severe Thrombocytopenia
Intervention: Drug: oprelvekin
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Adhesive Capsulitis
Intervention: Device: Dynasplint
Sponsors: Dynasplint Systems, Inc.; Dynasplint Systems, Inc.; McMurry University
Recruiting - verified May 2013 - Condition: Anterior Ischemic Optic Neuropathy
Intervention: Drug: Diagnostic procedures
Sponsors: Bayer; Bayer
Recruiting - verified May 2013 - Condition: HIV Infection
Intervention: Drug: All licensed antiretroviral medications
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); Copenhagen HIV Programme (CHIP) -- Copenhagen, Denmark; Medical Research Council (MRC) Clinical Trials Unit -- London, United Kingdom; The Kirby Institute for Infection and Immunity in Society; The Institute for Clinical Research at the Veterans Affairs Medical Center -- Washington, D.C., USA; French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); German Federal Ministry of Education and Research; NEAT - European AIDS Treatment Network; National Health and Medical Research Council, Australia; National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Mental Health (NIMH); National Institute of Neurological Disorders and Stroke (NINDS); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Abbott; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Merck; Tibotec Pharmaceutical Limited
Recruiting - verified May 2013 - Condition: Colorectal Cancer
Interventions: Drug: NKTR-102; Drug: irinotecan
Sponsors: Nektar Therapeutics; Nektar Therapeutics
Recruiting - verified April 2013 - Condition: Chronic Heart Failure
Interventions: Drug: Enalapril monotherapy; Drug: Aliskiren monotherapy; Drug: Aliskiren / Enalapril combination therapy
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2013 - Condition: Hodgkin Lymphoma
Interventions: Drug: Stanford V Chemotherapy; Radiation: Radiation Therapy
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified May 2013 - Condition: Invasive Aspergillosis
Intervention: Drug: Voriconazole
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Cardiovascular Disease
Intervention: Procedure: Cardiac MRI
Sponsors: Cedars-Sinai Medical Center; Cedars-Sinai Medical Center; National Heart, Lung, and Blood Institute (NHLBI); University of Florida; University of Pittsburgh
Recruiting - verified May 2013 - Conditions: Peripheral Arterial Disease; Cardiovascular Disease
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2013 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: everolimus; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified May 2013 - Condition: Solid Tumors
Intervention: Drug: axitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Traumatic Brain Injury
Intervention: Drug: Progesterone
Sponsors: Emory University; David Wright
Recruiting - verified May 2013 - Conditions: Low-grade Glioma; Astrocytoma; Oligodendroglioma; Mixed Oligoastrocytoma
Intervention: Drug: RAD001
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified May 2013 - Condition: Candidiasis
Interventions: Drug: micafungin; Drug: amphotericin B deoxycholate
Sponsors: Astellas Pharma Inc; Astellas Pharma Global Development, Inc.
Recruiting - verified April 2013 - Condition: Brain Injuries
Intervention: Drug: NNZ-2566
Sponsors: Neuren Pharmaceuticals Limited; Neuren Pharmaceuticals Limited
Recruiting - verified May 2013 - Condition: Breast Cancer
Intervention: Procedure: contrast-enhanced magnetic resonance imaging
Sponsors: University of California, San Francisco; University of California, San Francisco; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Nicotine Dependence; Alcohol Dependence
Interventions: Drug: Topiramate; Drug: Placebo
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2013 - Condition: Human Immuno Deficiency (HIV) Infections
Interventions: Drug: TMC278; Drug: Zidovudine; Drug: Abacavir; Drug: Tenofovir disoproxil fumarate; Drug: Lamivudine; Drug: Emtricitabine
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified May 2013 - Conditions: Parkinson's Disease; Dystonia
Interventions: Procedure: interventional MRI for implantation of DBS electrodes; Device: DBS electrodes
Sponsors: University of California, San Francisco; University of California, San Francisco; Surgi-Vision Inc; National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Recruiting - verified May 2013 - Condition: Human Immunodeficiency Virus (HIV)
Intervention: Drug: Maraviroc
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2013 - Condition: Healthy
Intervention: Drug: Filgrastim
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified May 2013 - Conditions: Acute Myocardial Infarction (AMI); Coronary Occlusion; Acute Coronary Syndrome
Intervention: Device: AngelMed Guardian System
Sponsors: Angel Medical Systems; Angel Medical Systems; Symbios Clinical
Recruiting - verified May 2013 - Conditions: Deep Vein Thrombosis; Venous Thrombosis; Postphlebitic Syndrome; Venous Thromboembolism; Post Thrombotic Syndrome
Intervention: Drug: Recombinant tissue plasminogen activator (rt-PA)
Sponsors: Washington University School of Medicine; Washington University School of Medicine; McMaster University; Ontario Clinical Oncology Group (OCOG); National Heart, Lung, and Blood Institute (NHLBI); BSN Medical Inc; Genentech; Covidien; BayerHealthcare; Mid America Heart Institute; Society of Interventional Radiology Foundation; Massachusetts General Hospital
Recruiting - verified May 2013 - Condition: Degenerative Disc Disease (DDD)
Interventions: Device: FLD; Device: Control
Sponsors: AxioMed Spine Corporation; AxioMed Spine Corporation
Recruiting - verified May 2013 - Condition: Dystonia
Intervention: Device: Medtronic implantable deep brain stimulation (DBS) system
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified May 2013 - Condition: Severe Congenital Diaphragmatic Hernia
Intervention: Device: Percutaneous endoscopic fetal tracheal occlusion/unocclusion
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified May 2013 - Conditions: Sleep Initiation and Maintenance Disorders; Depression
Interventions: Drug: Antidepressant; Behavioral: Desensitization Therapy for Insomnia; Behavioral: Cognitive Behavioral Therapy for Insomnia
Sponsors: Stanford University; Stanford University; Duke University; University of Pittsburgh; University of Pennsylvania
Recruiting - verified April 2013 - Conditions: Candidemia; Candidiasis
Interventions: Drug: anidulafungin; Drug: fluconazole
Sponsors: Pfizer; Pfizer
Recruiting - verified October 2012 - Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Drug: cyclosporine ophthalmic emulsion; Other: placebo
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2013 - Condition: Methicillin-Resistant S.Aureus
Interventions: Drug: Trimethoprim-sulfamethoxazole (TS); Drug: Clindamycin; Drug: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2013 - Condition: Methicillin-Resistant S.Aureus
Interventions: Drug: Placebo; Drug: Trimethoprim-sulfamethoxazole (TS); Drug: Cephalexin; Drug: Clindamycin
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2012 - Condition: HIV Infections
Interventions: Behavioral: Skills-Building Intervention; Behavioral: Personal Interview Group
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified May 2013 - Condition: Meningococcal Disease
Intervention: Biological: Meningococcal vaccine GSK134612
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Acute Myeloid Leukemia
Interventions: Drug: Cytarabine; Drug: Daunorubicin; Drug: Etoposide; Drug: Clofarabine
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; Genzyme; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Aids-related Malignancies; Lymphoma; Precancerous Condition; Sarcoma
Interventions: Genetic: polymerase chain reaction; Other: cytology specimen collection procedure; Other: histological technique; Procedure: colposcopic biopsy
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
Interventions: Drug: sunitinib malate; Other: placebo; Procedure: quality-of-life assessment; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Chronic Obstructive Pulmonary Disease
Intervention: Behavioral: Supplemental oxygen therapy
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); Centers for Medicare and Medicaid Services
Recruiting - verified May 2013 - Condition: Sleep Apnea, Obstructive
Intervention: Drug: Propofol sedation
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified May 2013 - Condition: Lung Cancer, Non-Small Cell
Intervention: Procedure: Collection of tumor and blood samples
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified November 2012 - Condition: Bacterial Vaginosis
Intervention: Drug: Metronidazole
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2013 - Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified April 2013 - Condition: Career Development Grant Outcomes
Intervention: Other: Extensive Consultations
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified May 2013 - Condition: Kidney Transplantation
Interventions: Drug: Cyclosporine; Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: Psychotic Depression; Major Depression With Psychotic Features; Psychosis
Interventions: Drug: mifepristone; Drug: placebo
Sponsors: Corcept Therapeutics; Corcept Therapeutics
Recruiting - verified April 2013 - Conditions: Transthyretin Mutations; Transthyretin Amyloidosis
Intervention: Other: None. Observational Study.
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: Crohn's Disease; Ulcerative Colitis; Indeterminate Colitis; Inflammatory Bowel Diseases
Interventions: Biological: Anti TNF therapy including infliximab; Drug: No Biologics
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified May 2013 - Conditions: Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: melphalan; Drug: prednisone; Drug: thalidomide; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: Induction Chemotherapy; Drug: Low-Risk Therapy; Drug: High-Risk Therapy; Drug: Intermediate-Risk Therapy
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; University of Florida
Recruiting - verified May 2013 - Condition: Prostate Cancer
Intervention: Drug: RAD001, Docetaxel, Bevacizumab
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; Novartis; Genentech; University of Southern California
Recruiting - verified May 2013 - Condition: Estrogen Deficiency
Intervention:
Sponsors: Cedars-Sinai Medical Center; Cedars-Sinai Medical Center
Recruiting - verified May 2013 - Condition: Heart Disease
Intervention: Procedure: noninvasive tests
Sponsors: Cedars-Sinai Medical Center; Cedars-Sinai Medical Center
Recruiting - verified May 2013 - Condition: Influenza
Interventions: Drug: oseltamivir; Drug: oseltamivir; Other: Alternative Control
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Lumbar Spinal Stenosis
Intervention: Device: X-STOP PEEK
Sponsors: Medtronic Spine LLC; Medtronic Spine LLC
Recruiting - verified April 2013 - Conditions: Gastroesophageal Junction Adenocarcinoma; Gastric Cancer
Interventions: Drug: Docetaxel, Leucovorin, Fluorouracil, Cisplatin; Drug: Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Sanofi; Roche/Genetech; City of Hope National Medical Center; Piedmont Hospital Research Institute; Medical College of Wisconsin; Queens Health Network; Weill Medical College of Cornell University; Memorial Cancer Institute, Florida; University of Pittsburgh; Long Island Jewish Medical Center; Nebraska Cancer Specialists Methodist Estabrook Cancer Center
Recruiting - verified April 2013 - Condition: Kidney Transplant
Interventions: Drug: ramipril; Drug: ramipril
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Condition: Endometrial Cancer
Interventions: Drug: cisplatin; Radiation: brachytherapy; Radiation: external beam radiation therapy
Sponsors: Gynecologic Oncology Group; Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Neoplasms, Breast; Breast Cancer
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline; North Central Cancer Treatment Group; National Cancer Institute (NCI); Breast International Group; NCIC Clinical Trials Group
Recruiting - verified May 2013 - Condition: HIV Infections
Interventions: Drug: Raltegravir (MK-0518); Drug: Raltegravir (MK-0518); Drug: Raltegravir (MK-0518)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013 - Conditions: Thoracoabdominal Aortic Aneurysm; Paravisceral Abdominal Aortic Aneurysm
Intervention: Device: Endovascular Branched Stent-Graft
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified May 2013 - Condition: Crohn's Disease
Interventions: Drug: adult human mesenchymal stem cells; Drug: Placebo
Sponsors: Osiris Therapeutics; Osiris Therapeutics
Recruiting - verified May 2013 - Condition: HIV Infections
Interventions: Drug: Emtricitabine/tenofovir disoproxil fumarate; Drug: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Bill and Melinda Gates Foundation
Recruiting - verified May 2013 - Condition: Lumbar Degenerative Disc Disease
Interventions: Device: DIAM™ Spinal Stabilization System; Procedure: Conservative care
Sponsors: Medtronic Spinal and Biologics; Medtronic Spinal and Biologics
Recruiting - verified April 2013 - Condition: Epilepsies, Partial
Intervention: Drug: Pregabalin
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Condition: Diabetes Mellitus, Type 1
Intervention: Drug: Oral Insulin
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Allergy and Infectious Diseases (NIAID); National Center for Research Resources (NCRR); American Diabetes Association; Juvenile Diabetes Research Foundation
Recruiting - verified May 2013 - Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: Mycoses; Candidiasis, Invasive; Candidemia
Interventions: Drug: Isavuconazole; Drug: Caspofungin; Drug: Voriconazole
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Basilea Pharmaceutica
Recruiting - verified May 2013 - Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Retinitis Pigmentosa; Inherited Ophthalmic Diseases
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Eye Institute (NEI)
Recruiting - verified May 2012 - Conditions: Systemic Sclerosis; Scleroderma; Pulmonary Hypertension; Pulmonary Arterial Hypertension
Intervention:
Sponsors: Georgetown University; Georgetown University; Gilead Sciences
Recruiting - verified May 2013 - Conditions: Prostatic Neoplasms; Prostate Cancer
Intervention:
Sponsors: Stanford University; Stanford University
Recruiting - verified May 2013 - Conditions: Corneal Dystrophies, Hereditary; Corneal Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Eye Institute (NEI)
Recruiting - verified July 2012 - Condition: Epilepsies, Partial
Interventions: Drug: Lyrica (pregabalin); Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Conditions: Arthritis, Rheumatoid; Osteoarthritis
Interventions: Drug: celecoxib; Drug: Ibuprofen; Drug: Naproxen
Sponsors: Pfizer; Pfizer; The Cleveland Clinic
Recruiting - verified May 2013 - Conditions: Breast Cancer; Neoplasm Metastasis
Interventions: Other: Standard supportive care (packed RBC transfusion); Drug: epoetin alfa + packed RBC transfusion
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2013 - Conditions: Seizures; Epilepsies, Partial; Epilepsy, Complex Partial; Epilepsy, Generalized; Epilepsy
Interventions: Drug: Placebo; Drug: Vanquix Auto-Injector (Diazepam Injection)
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Procedure: adjuvant therapy
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified May 2013 - Conditions: Brain Disorders; Aicardi Syndrome
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco; University of Washington; California Institute of Technology
Recruiting - verified May 2013 - Condition: Lymphoma, B-Cell
Interventions: Drug: inotuzumab ozogamicin; Drug: inotuzumab ozogamicin; Drug: inotuzumab ozogamicin
Sponsors: Pfizer; Pfizer; UCB, Inc.
Recruiting - verified May 2013 - Conditions: Cervical Adenocarcinoma; Cervical Adenosquamous Cell Carcinoma; Cervical Squamous Cell Carcinoma; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer
Interventions: Drug: cisplatin; Drug: tirapazamine
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI); NCIC Clinical Trials Group
Recruiting - verified May 2013 - Condition: Kidney Transplantation
Interventions: Drug: Tacrolimus; Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Retinitis Pigmentosa
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco; University of California, Berkeley
Recruiting - verified May 2013 - Conditions: Retinal Degeneration; Retinitis Pigmentosa
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Eye Institute (NEI)
Recruiting - verified December 2012 - Condition: Postoperative Pain
Intervention: Drug: Gabapentin
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified May 2013 - Conditions: Leukemia; Lymphoma; Hematologic Diseases
Intervention: Procedure: collection and storage of tissue samples for research
Sponsors: Stanford University; Stanford University; National Cancer Institute (NCI); National Institutes of Health (NIH)
Recruiting - verified May 2013 - Conditions: Brain Cancer; Arthritis, Rheumatoid; Central Nervous System Neoplasms; Glioma
Intervention: Radiation: [18F]FHBG
Sponsors: Stanford University; Stanford University
Recruiting - verified May 2013 - Condition: HIV Infection
Intervention: Drug: Efavirenz
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Available - verified May 2013 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel; Drug: paclitaxel poliglumex; Other: clinical observation
Sponsors: Gynecologic Oncology Group; Gynecologic Oncology Group; National Cancer Institute (NCI); CTI
Recruiting - verified May 2013 - Condition: HIV Infections
Intervention: Drug: Tipranavir
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Available - verified May 2013 - Condition: Attention Deficit Disorder With Hyperactivity
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified October 2012 - Conditions: Glioblastoma Multiforme; Glioblastoma; GBM; Grade IV Astrocytoma; Glioma; Brain Cancer; Brain Tumor
Intervention: Drug: Dendritic cell immunotherapy
Sponsors: Northwest Biotherapeutics; Northwest Biotherapeutics
Recruiting - verified May 2013 - Condition: Neuroblastoma
Interventions: Drug: buthionine sulfoximine; Drug: melphalan; Procedure: Peripheral blood stem cell infusion; Other: Filgrastim
Sponsors: New Approaches to Neuroblastoma Therapy Consortium; New Approaches to Neuroblastoma Therapy Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2013 - Conditions: Malformations; Multiple Abnormalies; Polydactyly
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified March 2013
 |
Research Studies California - Join Reasearch Studies and clinical trials in California |
Clinical Trial Locations 